5-methoxy-n, n-dimethyltryptamine for treatment of anxiety

Through intravenous administration of 5-MeO-DMT, combined with specific dosages and dosing regimens, the problems of inefficient and inadequate tolerance of existing anxiety treatment methods have been solved, significantly improving clinical response rate and treatment safety, and reducing the risk of Anxiety and related sleep disorders.

CN118946352APending Publication Date: 2024-11-12GH RES IRELAND LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202380030911.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-01-30
Filing Date
2023-03-27
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing treatment methods for anxiety disorders are inefficient, the patient's response rate and tolerance are insufficient, and there are safety and tolerance problems during the treatment process, making it difficult to effectively improve mental or neurological diseases related to anxiety.

Method used

Provide peak psychedelic experience doses for treatment with 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or its pharmaceutically acceptable salts Anxiety, combined with specific dosage ranges and dosing regimens, optimize treatment effects.

Benefits of technology

Significantly improves the clinical response rate and durability of responses in patients, improves the safety and tolerance of treatment, increases patient compliance, reduces or eliminates anxiety symptoms, and improves anxiety-related sleep disorders in some patients .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005062311240000071
    Figure BDA0005062311240000071
  • Figure BDA0005062311240000081
    Figure BDA0005062311240000081
  • Figure BDA0005062311240002501
    Figure BDA0005062311240002501
Patent Text Reader

Abstract

5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT), or a pharmaceutically acceptable salt thereof, for use in the treatment of a patient suffering from anxiety wherein the 5-MeO-DMT, or a pharmaceutically acceptable salt thereof, is administered via the intravenous, intramuscular or subcutaneous route.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to an improved method for treating anxiety. Patients suffering from anxiety disorders experience anxiety, but this is also a symptom of other mental or neurological disorders.

[0002] Treatment includes administering a therapeutically effective amount of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof to patients in need. Background Technology

[0003] Anxiety is a feeling of unease and worry. Feeling anxious occasionally is a normal part of life.

[0004] However, individuals with anxiety disorders often experience intense, excessive, and persistent worry and fear about everyday situations.

[0005] Anxiety disorders typically involve recurrent episodes of sudden, intense anxiety, fear, or panic that peak within minutes (panic attack).

[0006] These feelings of anxiety and panic can interfere with daily activities, are difficult to control, are disproportionate to the actual danger, and can last for a long time. Avoidance behaviors can be adopted to prevent these feelings.

[0007] Anxiety can be idiopathic or occur within medical conditions such as mental disorders or neurological disorders. In fact, several mental and neurological disorders are known to be associated with anxiety. Patients with certain medical conditions may also experience anxiety, leading to related mental or neurological disorders.

[0008] Anxiety can not only severely impact quality of life, but it can also lead to or exacerbate other mental and physical disorders, such as depression, cognitive impairment, sleep disorders (e.g., insomnia), substance abuse, digestive or intestinal problems, headaches and chronic pain, social isolation, daily living problems, and suicide, which may be associated with anxiety disorders or other mental health disorders.

[0009] Currently, there are limited treatment options for anxiety disorders.

[0010] Therefore, there is a need for improved treatment of such disorders, particularly for anxiety associated with mental or neurological disorders, and for patients with certain medical conditions that lead to related mental or neurological disorders. Summary of the Invention

[0011] One object of the present invention is particularly to provide a treatment that is more effective than previously described treatments (i.e., a) a larger percentage of patients experience a clinical response, b) a larger average clinical response, c) an earlier clinical response, and / or d) a more durable clinical response).

[0012] A further object of the present invention is to provide compounds for improved psychoactive therapies and administration regimens for said therapies, said therapies having better safety and / or better tolerability than previously described therapies. Another object of the present invention is to provide compounds for improved psychoactive therapies and administration regimens for said therapies, said therapies being more convenient than previously described therapies. Another object of the present invention is to provide compounds for improved psychoactive therapies and administration regimens for said therapies, said therapies being associated with higher patient adherence rates (including higher treatment initiation rates) compared to previously described therapies. A further object of the present invention is to identify specific disease aspects and subgroups of specific disease aspects that may benefit from such improved psychoactive therapies.

[0013] This invention provides 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for the treatment of patients suffering from anxiety. Patients may suffer from anxiety disorders, mental or neurological disorders, and subthreshold anxiety, or may have comorbid anxiety and disorders requiring further diagnosis.

[0014] Anxiety can occur in patients with mental or neurological disorders, such as disorders characterized by depressive episodes, such as major depressive disorder (MDD), postpartum depression (PPD), persistent depressive disorder, seasonal affective disorder, and bipolar disorder (BD), such as bipolar I and bipolar II; anxiety disorders, such as separation anxiety disorder, agoraphobia, generalized anxiety disorder (GAD), social anxiety disorder (SAD), panic disorder, phobias, and substance / drug-induced anxiety disorders; somatic symptom disorders; obsessive-compulsive disorder (OCD) and related disorders, such as obsessive-compulsive disorder (OCD). Disorders of the mind (OCD) and physical dysmorphic disorder (BDD); post-traumatic stress disorder (PTSD); pain disorders such as chronic pain, fibromyalgia, and migraine; mental and behavioral disorders due to the use of psychoactive substances, such as substance use disorder (SUD); psychotic disorders such as schizophrenia; Parkinson's disease; dementia such as Alzheimer's dementia (AD), Parkinson's dementia (PDD), Lewy body dementia, vascular dementia, and frontotemporal dementia; eating disorders; attention deficit hyperactivity disorder (ADHD); personality disorders such as schizotypal personality disorder and borderline personality disorder; autism spectrum disorder; chronic fatigue syndrome; or medical conditions that lead to related mental or neurological disorders, such as anxiety caused by traumatic brain injury (TBI), HIV infection, or the sequelae of COVID.

[0015] Patients may also suffer from anxiety-related sleep disorders.

[0016] The present invention also provides dosage ranges and administration regimens that can be used to treat anxiety.

[0017] In the context of this invention, 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered via intravenous, intramuscular, or subcutaneous administration.

[0018] 5-MeO-DMT or a pharmaceutically acceptable salt thereof may be administered at a dose or dosing regimen that induces a peak psychedelic experience in the patient. A dose of approximately 1 mg to approximately 10 mg of 5-MeO-DMT or an equimolar amount of a pharmaceutically acceptable salt may be administered. Detailed Implementation

[0019] definition

[0020] As used in the context of this invention, unless otherwise stated, the term "5-MeO-DMT" refers to the free base 5-MeO-DMT. Pharmaceutically acceptable salts of 5-MeO-DMT may also be considered. Such salts are particularly acid addition salts, wherein the acid may be selected from, for example, acetic acid, benzoic acid, citric acid, fumaric acid, hydrobromic acid, hydrochloric acid, hydrofluoric acid, hydroiodic acid, oxalic acid, succinic acid, and trifluoromethanesulfonic acid. A preferred example is hydrobromide. It can be assumed that equimolar amounts are used, and the appropriate weight of the salt to be applied is calculated based on the weight of the free base.

[0021] As used in the context of this invention, the “patient” to be treated is a human subject who has been diagnosed by a practicing professional in accordance with recognized medical practice as having anxiety or a mental or neurological disorder related to anxiety. In the latter case, assessing anxiety may or may not be part of the diagnosis.

[0022] For example, the diagnosis of mental disorders or neurological disorders can be made according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) published by the American Psychiatric Association. The diagnosis will be made by a physician or psychologist. It is insufficient for the subject to believe that they have the aforementioned disorder.

[0023] As used in the context of this invention, unless otherwise stated, the terms "treating" and "treatment" shall include the management and care of a patient for the purpose of combating a disease, ailment, or disorder, and include the administration of compounds and methods according to the invention to alleviate the signs and / or symptoms of a disease or to eliminate the disease, ailment, or disorder.

[0024] "Treatment of anxiety" should include the management and care of patients for the purpose of combating anxiety, and includes the administration of compounds and methods according to the invention to reduce the signs and / or symptoms of anxiety or to eliminate anxiety.

[0025] The patient may suffer from anxiety disorder or anxiety-related disorder. Anxiety may be associated with sleep disturbances.

[0026] The patient may have a treatment-resistant disorder. Treatment resistance means that the patient has not achieved adequate improvement after at least two adequate courses of treatment. This is particularly true when the patient has not achieved adequate improvement after at least two adequate courses of treatment, where at least one of these courses is pharmacological therapy; for example, the patient has not achieved adequate improvement after at least two adequate courses of medication. Specifically, this involves the administration of at least two prior courses of treatment during the current episode of the disorder, for example, if the patient suffers from a disorder characterized by depressive episodes, administration during the current depressive episode.

[0027] As used in the context of this invention, "suicidal ideation" means thinking, considering, or planning suicide. A physician or psychologist will use established protocols and methods for diagnosing suicidal tendencies to diagnose whether a patient has suicidal ideation. Generally, it is not sufficient for a patient to believe they have suicidal ideation. In some cases, a patient with suicidal ideation will face an imminent risk of suicide or be considered to have "suicidal intent."

[0028] As used in the context of this invention, unless otherwise stated, the term "therapeutic effective amount" should mean the amount of an active compound or pharmaceutical ingredient that elicits a biological or clinical response in humans sought by a researcher, physician, or other clinician, including relief of signs and / or symptoms of the disease, disorder, or impairment being treated.

[0029] "Clinical response" includes, but is not limited to, improvement on rating scales. These scales assess (i) anxiety or aspects of anxiety and / or (ii) mental or neurological disorders or aspects of such disorders.

[0030] The severity of a disease and changes in severity can be assessed using the Clinical Global Impression (CGI) rating scale, which measures symptom severity, treatment response, and treatment efficacy.

[0031] The CGI rating scale was developed to provide clinicians with a concise and independent assessment of their views on patients’ overall functioning before and after treatment (Busner, J. and Tagrum, SD, 2007. The Clinical Global Impressions Scale: Applying a Research Tool in Clinical Practice. Psychiatry 2007, 29-37).

[0032] CGI Severity (CGI-S) is based on a question that clinicians must answer: “Given your overall clinical experience with this particular population, how severe is the patient’s current psychosis?” It is assessed using the following seven-point scale: 1 = Normal, no symptoms at all; 2 = Borderline psychosis; 3 = Mild symptoms; 4 = Moderate symptoms; 5 = Severe symptoms; 6 = Severe symptoms; 7 = Most severe symptoms.

[0033] The CGI-S can be used to assess treatment success by comparing scores before and after treatment.

[0034] Alternatively, CGI-I (CGI-I) can be used to assess treatment success, and its format is equally simple. After treatment, the clinician compares the patient's overall clinical condition to their pre-treatment condition (the so-called baseline). Again, only one question is assessed using a seven-point scale: "Compared to the patient's condition at admission (before starting medication), the patient's condition: 1 = Very significant improvement since treatment began; 2 = Significant improvement; 3 = Slight improvement; 4 = No change from baseline (at the start of treatment); 5 = Slight deterioration; 6 = Significant deterioration; 7 = Very significant deterioration since treatment began."

[0035] The Patient Global Impression Scale (PGI), also known as the Subject Global Impression (SGI), is the counterpart to the Clinical Global Impression Scale (CGI). It consists of a CGI-based, patient-specific item. It can measure disease severity (PGI-S) or disease improvement (PGI-I).

[0036] Individual items and sub-combinations of individual items from the scales described in this article can be used to assess specific disease aspects.

[0037] As used in the context of this invention, unless otherwise stated, the term "application" (or "administration") shall mean the introduction of a certain amount (which may be a predetermined amount) of an active compound or pharmaceutical ingredient into a patient via any route. The active compound may be administered intravenously, intramuscularly, or subcutaneously.

[0038] As used in the context of this invention, unless otherwise stated, the terms "dose," "dosage," and "dosage amount" shall mean the amount of an active compound or pharmaceutical ingredient administered to a patient in a single administration. The term "dosing regimen" (or "administration regimen") shall mean a defined sequence of single or multiple administrations.

[0039] anxiety

[0040] Anxiety is sometimes defined as “anxious anticipation of future danger or misfortune, accompanied by feelings of restlessness or physical symptoms of tension.”

[0041] Anxiety is characterized by intense, excessive, and persistent worry and fear of situations that are perceived as threatening only subjectively, and is often accompanied by muscle tension, restlessness, fatigue, difficulty breathing, abdominal tightness, nausea, and difficulty concentrating.

[0042] In anxiety disorders or other mental or neurological disorders related to anxiety, feelings of anxiety are difficult to control and interfere with daily activities.

[0043] Anxiety is a core feature of anxiety disorders, including separation anxiety disorder, specific phobias, social anxiety disorder (social phobia), panic disorder, generalized anxiety disorder (GAD), agoraphobia, and substance / drug-induced anxiety disorders.

[0044] In addition, anxiety is associated with several other mental and neurological disorders. Anxiety is also linked to sleep disturbances.

[0045] Measuring anxiety

[0046] Several rating scales for assessing anxiety are known in the art, and anxiety symptoms are also assessed as part of various rating scales for assessing mental and neurological disorders.

[0047] The Hamilton Anxiety Rating Scale (HAM-A) is designed to assess anxiety symptoms. The scale is administered by a clinician. It consists of 14 items, divided into a mental item group (items 1-6 and 14), which measures mental agitation and psychological distress, and a physical item group (items 7-13), which measures physical discomfort associated with anxiety.

[0048] The HAM-A project is shown in the table below.

[0049]

[0050]

[0051] Interviewers rated each item on a scale of 0 to 4: 0 = not present, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe.

[0052] The total score is calculated by adding up 14 items. The total score ranges from 0 to 56. A higher score indicates greater anxiety.

[0053] A score of ≤7 is considered to indicate no anxiety or very low anxiety; a score of 8-14 indicates mild anxiety; a score of 15-23 indicates moderate anxiety; and a score of ≥24 indicates severe anxiety.

[0054] The Beck Anxiety Scale (BAI) is a 21-item self-report questionnaire developed to assess anxiety, with a focus on physical symptoms. The items are rated on a four-point Likert scale, ranging from zero (absolutely none) to three (severe: I can barely tolerate it). The total score ranges from 0 to 63.

[0055] The term “subthreshold anxiety” as used in this article specifically refers to a patient’s Hamilton Anxiety Rating Scale (HAM-A) score of at least 9 but less than 18, and / or a Beck Anxiety Scale (BAI) score of at least 11 but less than 16.

[0056] Scales for assessing mental and neurological disorders

[0057] Several scales have been developed to assess the severity of mental or neurological disorders. These scales are based on tests that can be self-administered or administered by a clinician.

[0058] The scales that can be used according to the invention include those known in the art for diagnosing and / or monitoring mental or neurological disorders, which are discussed in more detail below.

[0059] Treatment outcomes are assessed using one or more indices or scales at one or more time points after the completion of the treatment process.

[0060] Assessment can be performed after the acute psychedelic experience has subsided. The appropriate time for early assessment is typically about 2 to 3 hours after the last administration. Early assessment can usually be performed, for example, about 2 or 3 hours after the last administration.

[0061] However, the impact of the sleep disorder can be assessed as early as the second day after treatment (i.e., day 1), giving the treated patient the opportunity to sleep for at least one night.

[0062] Therefore, the assessment on day 1 or day 1 means the assessment on the second day after application. The assessment shall be performed no earlier than 12 hours after the last application, and in any event no earlier than the night after the last application, and no later than 36 hours after the last application. An assessment may be performed approximately 24 hours later.

[0063] The assessment on day 7 or day 7 refers to an assessment performed on the seventh day after application (day 0 is the day of application). A similar definition applies to other assessment times measured in days.

[0064] When assessing clinical response at an early time point after drug administration (e.g., 2 hours), such as when using one of the scales described to assess the severity of a mental or neurological disorder, the endpoint can be reasonably modified based on the endpoint developed for a longer recall period (e.g., the MADRS is typically 7 days). This could be done by changing the MADRS recall period to 2 hours and carrying over the sleep item from the baseline record prior to drug administration. Unless a recall period is specifically specified, this also applies to any other scales used herein.

[0065] The considerations outlined apply to earlier time points because, on the one hand, the patient’s condition before treatment should have as little influence as possible on any scores recorded after treatment in order to assess clinical response, and on the other hand, sleep items cannot be assessed 2 hours after medication administration.

[0066] At a later point in time, such as on day 1 or later, an appropriate recall period (if necessary) can often be used to assess all items of the relevant scales used to assess clinical response, so that no pre-treatment scores need to be carried forward.

[0067] The Brief Psychiatric Rating Scale (BPRS) is designed to screen for psychiatric symptoms in a structured manner. It is one of the most widely used scales for measuring psychotic symptoms and was first published in 1962. The design has since been updated. The most commonly used version today includes 18 different domains for evaluation by physicians or psychologists (Generally speaking, JE and Gorham, DR, 1962. The Brief Psychiatric Rating Scale. Psychological Reports 10, p. 799; Generally speaking, JE and Gorham, DR, 1988. The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacology Bulletin 22, p. 97).

[0068] Eighteen items (physical focus, anxiety, emotional withdrawal, conceptual confusion, guilt, tension, behavior and posture, grandiosity, depressive mood, hostility, paranoia, hallucinations, bradykinesia, noncooperation, unusual thought content, emotional blunting, excitement, and disorientation) were rated, with each item assessed on a scale of 1-7.

[0069] During a roughly 15-minute interview with the patient, the doctor or psychologist will complete two tasks:

[0070] They will ask the patient a series of questions from a list.

[0071] They will examine whether the patient exhibits certain behaviors.

[0072] Based on the answers and observed behavior, the physician or psychologist will complete the BPRS form by ranking the severity of each area using a scale from one to seven: one indicates the absence of signs or symptoms, and seven indicates the presence of signs or symptoms at a severe level. If a specific sign or symptom cannot be assessed, a score of 0 or "not assessed" is recorded.

[0073] The Columbia Suicide Severity Rating Scale (C-SSRS) is a detailed questionnaire that assesses suicidal behavior and suicidal ideation to help identify whether immediate medical intervention is needed and to provide data for the overall assessment of treatment effectiveness associated with suicidal tendencies. The C-SSRS is evidence-supported and is part of national and international public health initiatives involving the assessment of suicidal tendencies (Posner, K., Brown, GK, Stanley, B., Brent, DA, Yershova, KV, Oquendo, MA, Currier, GW, Melvin, GA, Greenhill, L., Shen, S. and Mann, JJ, 2011. The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults. American Journal of Psychiatry 168(12), pp. 1266–77).

[0074] The underlying mechanisms of anxiety

[0075] Functional magnetic resonance imaging (fMRI) can be used to study brain processes. Brain activity is related to blood flow, and the temporal correlation of spontaneous oxygenation level-dependent (BOLD) signal fluctuations between different brain regions can be measured.

[0076] Functional imaging of the brain was obtained over several minutes. Low-frequency BOLD signal oscillation patterns were observed throughout the brain. Decomposition of this spontaneous signal revealed distribution areas with correlated and negatively correlated fluctuations.

[0077] In this way, resting-state fMRI can be used to characterize large-scale functional networks, known as resting-state networks (RSNs), which are a group of spatially distinct brain regions that exhibit coordinated activity in the absence of any explicit cognitive task (i.e., at rest). The observed patterns characterize networks of brain regions with coherent patterns of signal variation, which are referred to as resting-state networks (RSNs).

[0078] Based primarily on the spatial similarity between resting-state networks and activation patterns observed in task-based fMRI experiments, different resting-state networks have been identified and named.

[0079] Therefore, resting-state fMRI can be used to assess the brain's intrinsic functional organization. Resting-state networks are characterized by aspects of attention, memory, cognitive control, default modes, motor and sensory systems.

[0080] The resting-state network (RSN) has been shown to be responsible for various aspects of complex brain function, and these connectivity networks have been found to be impaired in a variety of disease states. Such disease states (including certain forms of anxiety) are associated with altered functional connectivity within a specific resting-state network and / or between one or more regions in one or more additional resting-state networks.

[0081] According to such studies, multiple brain regions are associated with anxiety and anxiety disorders. Therefore, the pathophysiology of anxiety and anxiety disorders involves abnormal connections between the amygdala-frontal lobe and the frontostriatal regions. Anxiety and anxiety disorders are also associated with specific alterations in the resting-state network.

[0082] Anxiety and anxiety disorders exhibit abnormalities within and / or between the default mode network, salience network, and sensorimotor network. The resting-state balance within and / or between each of these networks differs across different anxiety disorders.

[0083] Surfactant

[0084] The above discussion shows that anxiety itself can have a significant disease burden and requires appropriate treatment.

[0085] The inventors believe that carefully selected hallucinogens may lead to treatment that improves important aspects of anxiety and may result in an overall improvement of the disorder.

[0086] A group of hallucinogens contains compounds that bind to serotonin (5-HT) receptors, also known as serotonin receptors (described as a family of seven with several subtypes, 5-HT1 to 5-HT7). Examples include lysergic acid diacetamide (LSD), psilocybin, and N,N-dimethyltryptamine (DMT). These serotonin-like agents are often referred to as "psychedelics," highlighting their primary ability to induce qualitative changes in states of consciousness, such as euphoria, trance, changes in time and space, psychic experiences, loss of self-boundaries, or even near-death experiences, while other effects, such as sedation, anesthesia, or overstimulation, are negligible.

[0087] From a chemical perspective, serotonin psychedelics are either phenylalkylamines or indoleamines. Indoleamines are further divided into two subsets: ergoline and tryptamines, the latter of which are derived from tryptamines.

[0088] Various serotonin psychedelics have different binding affinities and activation efficacies for various serotonin receptors (especially 5-HT1A, 5-HT2A, and 5-HT2C), and their activity can also be modulated through interactions with other targets (such as monoamine transporters and trace amine-associated receptors).

[0089] Recent studies on the use of serotonin-containing psychedelic drugs (such as LSD, psilocybin, and DMT (using ayahuasca, a shamanic elixir containing DMT) in certain mental disorders suggest that these compounds could offer alternative treatments for some currently available mental disorders. However, there are reports that these compounds may induce mania in patients with depressive symptoms, which could hinder their clinical use.

[0090] For example, Lake et al. (Lake, CR, Stirba, AL, Kinneman, RE Jr, Carlson, B., Holloway, HC, 1981. Mania associated with LSD ingestion. American Journal of Psychiatry. 138(11): 1508-9) reported a case of a patient experiencing a manic episode after taking LSD or an LSD analogue. The patient presented with acute LSD intoxication symptoms, which were relieved, but a typical psychotic manic episode occurred approximately 3 weeks later. Hendin and Penn (Hendin, HM, Penn, AD, 2021. An episode of mania following self-reported ingestion of psilocybin mushrooms in a woman previously not diagnosed with bipolar disorder: A case report. BipolarDisorders 23(4): 1-3) reported a manic episode following self-reported ingestion of psilocybin mushrooms. Szmulewicz et al. (Szmulewicz, AG, Valerio, MP and Jose MSmith, JM, 2015. Switch to mania afterayahuasca consumption in aman with bipolar disorder: a case report. International Journal of Bipolar Disorders (2015) 3:4) reported a case report of a man with bipolar disorder who turned manic after drinking ayahuasca (a beverage containing DMT).

[0091] Another case report can be found in Brown, T., Shao, W., Ayub, S., Chong, D., & Cornelius, C. (2017). A Physician's attempt to self-medicate bipolar depression with N,N-dimethyltryptamine (DMT). Journal of Psychoactive Drugs, 49(4), 294-296.

[0092] The inventors believe that, in order to avoid inducing mania or mild mania, or at least reduce the risk of inducing mania or mild mania, it is necessary to properly select the compound to be administered and preferably administer it according to a specific dosing regimen.

[0093] The inventors have identified 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) as a psychedelic drug of particular interest for therapeutic purposes. 5-MeO-DMT possesses unique pharmacological properties that distinguish it from other psychedelic compounds.

[0094] 5-MeO-DMT is a potent, fast-acting, naturally occurring serotonin (5-HT) agonist that acts on 5-HT1A and 5-HT2A receptors, and has a higher affinity for the 5-HT1A receptor subtype compared to other classic psychedelic drugs.

[0095] The dephosphorylated psilocin (the dephosphorylated form of psilocin formed after psilocin uptake), DMT, and the inhibitory constants (Ka) of 5-HT1A receptors in the hippocampus of post-mortem human brains, as further detailed in the Examples section below, are described. i The inhibitory constants (K2) were 48, 38, and 1.80 nM, respectively. Therefore, 5-MeO-DMT exhibited high affinity for the 5-HT1A receptor, while dephosphorylated psilocybin and DMT showed moderate affinity. The inhibitory constants (K2) of dephosphorylated psilocybin, DMT, and 5-MeO-DMT at the 5-HT2A receptor located in the frontal cortex of the post-mortem human brain were... i The values ​​were 37, 117, and 122 nM, respectively. Therefore, dephosphorylated psilocybin showed moderate / strong affinity for the 5-HT2A receptor, while DMT and 5-MeO-DMT showed relatively weak affinity.

[0096] Compared to the other previously mentioned psychoactive compounds, 5-MeO-DMT exhibits enhanced affinity for the 5-HT1A receptor, in which case it acts as a potent agonist. In the cases of dephosphorylated psilocybin and DMT, the contribution of 5-HT2A binding is increased compared to 5-MeO-DMT, with 5-MeO-DMT exhibiting the greatest differential affinity for 5-HT1A relative to 5-HT2A among the three compounds. Therefore, compared to the other two compounds, 5-HT1A binding plays a much larger role in the overall effect of 5-MeO-DMT compared to 5-HT2A binding.

[0097] It has been reported that 5-HT1A agonists reduce impulsivity and aggression, while 5-HT2A agonists cause a short-term increase in these same traits. Furthermore, 5-HT1A agonists have anxiolytic effects. Additionally, the dopamine system is associated with mania, and an increase in dopamine drive is linked to mania. Compared to 5-MeO-DMT, LSD, psilocybin, and DMT exhibit increased affinity for multiple dopamine receptors.

[0098] Compared to other psychedelic drugs (such as LSD, psilocybin, or DMT), 5-MeO-DMT can be preferably administered to patients using the dosing regimen described herein without posing a significant risk of inducing mania or hypomania in patients with mental or neurological disorders, including disorders characterized by depressive episodes such as major depressive disorder (MDD), postpartum depression (PPD), persistent depressive disorder, seasonal affective disorder, and bipolar disorder (BD), such as bipolar I and bipolar II; psychotic disorders such as schizophrenia; or personality disorders such as schizotypal personality disorder. Patients with such mental or neurological disorders and treated according to the present invention will not experience treatment-induced mania or hypomania.

[0099] It is also noteworthy that reports of mania or hypomania induced by treatments involving the use of psychoactive substances appear to indicate the use of large amounts of the corresponding compounds (e.g., DMT / ayahuasca, psilocybin, LSD).

[0100] The inventors’ 5-MeO-DMT up-titration method significantly reduces the risk of overdose and the likelihood of associated adverse events.

[0101] Furthermore, it has been reported that antidepressants can induce isolated hypomanic events in patients with treatment-resistant depression (TRD) (Bader, Cynthia D., and David L. Dunner. "Antidepressant-induced hypomania in treatment-resistant depression." Journal of Psychiatric Practice 13.4 (2007):233-237). However, a recently completed clinical trial of 5-MeO-DMT in TRD patients did not show evidence of inducing hypomania.

[0102] 5-MeO-DMT can induce effervescent experiences (i.e., experiences characterized by a shift in emotional perspective, described as “loss of self”, typically ending in an overwhelming sense of “oneness with the universe”) more quickly than other psychedelics and has a shorter duration of acute psychedelic effects (5 to 30 minutes after intravenous injection, compared to several hours for, for example, oral psilocybin and oral LSD). These properties of 5-MeO-DMT are associated with an improved treatment profile, which can be explained by specific changes in resting state network (RSN) activity under 5-MeO-DMT treatment.

[0103] Furthermore, 5-MeO-DMT is a 5-HT7 receptor agonist with high affinity for the receptor. The inventors used recombinant human 5-HT7 receptor as a radioligand... 3 H]LSD and serotonin were used to estimate nonspecific binding, and K was measured. i It is 2.3 nM.

[0104] Therefore, in addition to the 5-HT1A and 5-HT2A receptors discussed above, 5-MeO-DMT also interacts with the 5-HT7 receptor. 5-MeO-DMT acts as an agonist for this receptor and exhibits high (nanomolar) binding affinity.

[0105] 5-HT7 receptors play a role in neurogenesis, synapsis, and dendritic spine formation. Among other things, they are associated with central processes such as learning and memory, sleep regulation and circadian rhythms, and nociceptive sensation.

[0106] 5-HT7 receptors are expressed in the spinal cord, raphe nuclei, thalamus, hypothalamus (including suprachiasmatic nucleus), hippocampus, prefrontal cortex, striatal complex, amygdala, and Purkinje neurons in the cerebellum.

[0107] The suprachiasmatic nucleus (SNU) is the central pacemaker of the circadian rhythm system. It coordinates the diurnal rhythms of various brain regions. Disruptions in this coordination can lead to disease states, particularly those involving sleep disorders. In patients with sleep disorders, resting-state functional connectivity analysis revealed altered functional connectivity between the SNU and regions within the default mode network.

[0108] The expression of the 5-HT7 receptor in the suprachiasmatic nucleus corresponds to the receptor's role in regulating the sleep / wake cycle. The inventors believe this allows for the treatment of patients with sleep disorders via 5-MeO-DMT that acts on the receptor.

[0109] The inventors believe that the binding of 5-MeO-DMT to the 5-HT7 receptor (which acts as a mediator for the pharmacological action of 5-MeO-DMT) involves the "resetting" of functional connectivity in networks and neuroplasticity effects, which may help 5-MeO-DMT to play a beneficial role in the treatment of patients with sleep disorders.

[0110] The inventors further believe that the binding of 5-MeO-DMT to both the 5-HT7 and 5-HT1A receptors (as two mediators in the action of 5-MeO-DMT) involves a "reset" of functional connectivity in the network and neuroplasticity effects, allowing for beneficial effects in patients with other symptoms or disorders, such as cognitive impairment, anxiety, psychomotor retardation, negative thinking, or social / emotional withdrawal. Clinical results from the studies cited in this article support this.

[0111] Another characteristic of 5-MeO-DMT is its short half-life.

[0112] 5-MeO-DMT is mainly inactivated via the monoamine oxidase A-mediated deamination pathway and is O-demethylated by cytochrome P450 2D6 (CYP2D6) enzyme.

[0113] The inventors studied the pharmacokinetic properties of 5-MeO-DMT and observed rapid absorption and distribution of inhaled 5-MeO-DMT, with maximum concentrations and pharmacological effects observed during and immediately after administration.

[0114] Pharmacokinetic analysis of inhaled 5-MeO-DMT showed a very rapid decline in plasma concentration. At 10 minutes post-administration, the concentration decreased to 10% or less of Cmax; after 2 hours, the concentration was 1% or less of Cmax; and after 3 hours, 5-MeO-DMT was no longer detectable in plasma. This applied to the full dose range tested (6 mg, 12 mg, 18 mg). No accumulation was observed after repeated administrations over a timeframe of 1 to 4 hours. Up-titration as disclosed herein does not lead to accumulation and therefore does not result in higher plasma concentrations, such as at 10 minutes, 2 hours, or 3 hours post-administration.

[0115] The properties of 5-MeO-DMT make the compound particularly suitable for treating anxiety, especially for patients with mental or neurological disorders, or medical conditions leading to related mental or neurological disorders; patients with sleep disturbances (e.g., insomnia); and patients with unspecified neurocognitive disorders.

[0116] The properties of 5-MeO-DMT also allow for specific dosing regimens, which are discussed in more detail below.

[0117] According to the present invention, isotopic variants of 5-MeO-DMT and pharmaceutically acceptable salts thereof may also be used. When referring to the use of 5-MeO-DMT or pharmaceutically acceptable salts thereof, the use of isotopic variants is also considered.

[0118] These variants are in particular the deuterated form of 5-MeO-DMT and pharmaceutically acceptable salts of such forms.

[0119] The deuterated form of 5-MeO-DMT is a form with a deuterium content higher than that expected based on the natural abundance of the isotope.

[0120] The deuterated form of 5-MeO-DMT is a specific form in which deuterium is introduced at one or more defined hydrogen sites.

[0121] Examples of deuterated forms of 5-MeO-DMT include, but are not limited to, 1-deuter-2-(5-methoxy-1H-indol-3-yl)-N,N-dimethylethylamine, 1,1-dideuter-2-(5-methoxy-1H-indol-3-yl)-N,N-dimethylethylamine, 1,1,2,2-tetradeuter-2-(5-methoxy-1H-indol-3-yl)-N,N-dimethylethylamine, and N,N-dimethyl-2-[5-(trideuteroxy)-1H-indol-3-yl]ethylamine.

[0122] Further examples include the form 5-MeO-DMT, in which deuterium has been introduced at one or more hydrogen positions of the N-bonded methyl group. Still further examples include the form 5-MeO-DMT, in which one or more deuterium atoms replace hydrogen atoms in the indole ring system. It is also worth noting that combinations of the above substitution modes are also possible.

[0123] The methods for preparing these compounds are known in the art.

[0124] According to the present invention, mixtures of deuterated forms of 5-MeO-DMT, mixtures of one or more deuterated forms with non-deuterated 5-MeO-DMT, pharmaceutically acceptable salts of deuterated forms of 5-MeO-DMT, mixtures of such salts, and mixtures of salts of deuterated 5-MeO-DMT and non-deuterated 5-MeO-DMT may also be used.

[0125] Furthermore, according to the present invention, the amounts of deuterated 5-MeO-DMT and deuterated 5-MeO-DMT salts used are equimolar with the amounts of the corresponding non-deuterated forms.

[0126] According to the present invention, a prodrug of 5-MeO-DMT and a pharmaceutically acceptable salt of such a prodrug can also be used. Such a prodrug of 5-MeO-DMT can be metabolized into 5-MeO-DMT. Therefore, when referring to the use of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, 5-MeO-DMT prodrug or a salt thereof can be used instead.

[0127] In a suitable prodrug, the hydrogen at position 1 of the indole moiety is replaced by an organic moiety that can be separated after administration.

[0128] A suitable example of an organic moiety is C(O)OR 1 -C(O)R 2 -CH(R) 3 OR 4 -C(O)OCH(R) 3 )OC(O)R 4 -C(O)OCH(R) 3 )OC(O)OR 4 -CH(R) 3 )C(O)R 4 -CH(R) 3 )OC(O)R 4 -CH(R) 3 )OC(O)OR 4 , where R 1 R 2 R 3 and R 4 Each of them is independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein each alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently substituted or unsubstituted.

[0129] A preferred example of an organic moiety is -CH(R) 3 )OC(O)R 4 and -C(O)OR 1 , where R 1 R 3 and R 4 As defined above.

[0130] Prodrugs, especially those with the above-described structures, can also be used in pharmaceutically acceptable salt form.

[0131] Specific examples of prodrugs are 5-MeO-DMT carboxyisopropylvaline ester, preferably in salt form, particularly as ditrifluoroacetate (1-(((S)-2-amino-3-methylbutyryl)oxy)-2-methylpropyl 3-(2-(dimethylamino)ethyl)-5-methoxy-1H-indole-1-carboxylic acid ditrifluoroacetate and 5-MeO-DMT methyl neopentanoate (3-(2-(dimethylamino)ethyl)-5-methoxy-1H-indole-1-yl)methyl neopentanoate).

[0132] The methods for preparing prodrugs, as discussed herein, are known in the art.

[0133] According to the present invention, the T value of the metabolite 5-MeO-DMT was measured in male Sprague-Dawley (SD) rats before and after oral administration at 10 mg / kg. max The value is preferably 1 hour or less, more preferably 0.7 hours or less, and especially 0.5 hours or less.

[0134] Furthermore, according to the present invention, the amounts of the 5-MeO-DMT prodrug and the salt of the 5-MeO-DMT prodrug are equimolar with the amounts of the corresponding non-prodrug forms.

[0135] Application mode

[0136] Therapeutic doses of 5-MeO-DMT are administered via intravenous, intramuscular, or subcutaneous administration. These routes ensure rapid onset of action. The preferred route of administration is intravenous, i.e., intravenous injection.

[0137] 5-MeO-DMT may be used in the form of a pharmaceutically acceptable salt, preferably hydrobromide, or in the form of a formulation administered by injection, examples of excipients and mediators of such formulations are known in the art.

[0138] Dosing regimen

[0139] The present invention also provides dosage ranges, specific dosages, administration regimens (application regimens), and appropriate routes of administration.

[0140] This invention is partly based on the inventors’ conclusion that peak psychedelic experiences occur during the acute phase following administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, which drives therapeutic benefits of 5-MeO-DMT or a pharmaceutically acceptable salt thereof for patients suffering from anxiety, particularly one or more aspects as defined above, said therapeutic benefits either causally or at least as alternative behavioral markers of potential unknown therapeutic mechanisms.

[0141] Therefore, achieving peak experience more quickly in a larger proportion of patients and having better repeatability in individual patients will lead to a better treatment profile compared to previously tested psychedelics, dosing regimens, and routes of administration.

[0142] Furthermore, this invention relies on the short duration of action and absence of associated tolerability of 5-MeO-DMT (i.e., no diminishing or disappearance of psychedelic effects after reapplication) as the basis for a dosing regimen that enables frequent reapplication (such as more than once daily or once daily), designed to increase the incidence of peak experiences and thus increase therapeutic benefits. Such repeated administration over a short period also allows for intra-individual dose optimization, which reduces the risk of overdose that could otherwise lead to physical side effects such as serotonin syndrome, negative psychological reactions (such as flashbacks at later points in time), induction of mania or hypomania, or psychedelic experiences with little or no meaningful memory of altered states (so-called "albinism"). Moreover, starting at a low dose allows patients to become familiar with general psychedelic experiences and prepares them for more intense symptoms at higher doses, which will positively impact the experience at higher doses. Furthermore, the prospect of being able to start treatment at a low dose will increase patient acceptance of the treatment and improve overall adherence at the patient population level.

[0143] Frequent reapplication of serotonin psychedelics can increase the frequency and repeatability of peak experiences, and improve treatment efficacy, reduce side effects, and increase compliance, which may not be possible with other psychedelics because the psychedelic effects take effect later and last longer, and tolerance develops rapidly (i.e., the psychedelic effects diminish or disappear after reapplication), and this tolerance may last for several days.

[0144] Patients suffering from anxiety as defined herein may be treated by administering 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0145] In a preferred embodiment, 5-MeO-DMT is administered as a monotherapy, meaning the patient does not receive any other anxiety treatment.

[0146] The dosage range of 5-MeO-DMT administered to patients suffering from anxiety as defined herein is from about 1 mg to about 10 mg, or any range thereof, and is administered in the form of an administration formulation based on a pharmaceutically acceptable salt of 5-MeO-DMT (such as hydrobromide), the weight of which may be calculated based on the prescribed weight of the free base of 5-MeO-DMT, assuming the use of equimolar amounts. Useful specific amounts of 5-MeO-DMT are, for example, about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, and about 10 mg. Note that in this specification, when ranges are listed (such as “about 1 mg to about 10 mg”), the inventors have considered all discrete values ​​within that range, some of which are explicitly mentioned, but not all – this is merely for the purpose of brevity.

[0147] In a preferred embodiment, an improved method of treating patients with anxiety as defined herein using a therapeutically effective amount of 5-MeO-DMT includes the appearance of a clinical response no later than about 2 hours after administration of 5-MeO-DMT.

[0148] In a preferred embodiment, an improved method of treating patients with anxiety as defined herein using a therapeutically effective amount of 5-MeO-DMT includes a sustained clinical response, including a clinical response that appears no later than about 2 hours after administration of 5-MeO-DMT and persists for at least about 6 days after the last administration of 5-MeO-DMT, preferably for at least about 14 days after the last administration of 5-MeO-DMT, and more preferably for at least about 28 days after the last administration of 5-MeO-DMT.

[0149] In a preferred embodiment, an improved method of treating patients with anxiety as defined herein using a therapeutically effective amount of 5-MeO-DMT includes administering more than a single dose of 5-MeO-DMT.

[0150] In a preferred embodiment, the patient is given more than a single dose of 5-MeO-DMT in one or more treatment blocks, each block consisting of 2 to 7 administrations, with an interval of not less than about 1 hour and not more than about 24 hours between administrations within each treatment block, and an interval of not less than about 6 days between the end of one treatment block and the start of the next treatment block.

[0151] In an even more preferred embodiment, the patient is given more than a single dose of 5-MeO-DMT in one or more treatment blocks, each block consisting of 1 to 3 administrations, with an interval of about 24 hours between each administration within each treatment block, and an interval of not less than about 6 days between the end of one treatment block and the start of the next treatment block.

[0152] In the most preferred embodiment, the patient is given more than a single dose of 5-MeO-DMT in one or more treatment blocks, each block consisting of 1 to 3 administrations, with an interval of about 1 to 4 hours, preferably 1 to 2 hours, between each administration within each treatment block, and the interval between the end of one treatment block and the start of the next treatment block is not less than about 6 days.

[0153] In the implementation scheme, the dose of 5-MeO-DMT administered to an individual patient in each application and in each treatment block is constant for that individual patient and is selected from about 1 mg to about 10 mg.

[0154] In a preferred embodiment, the dose of 5-MeO-DMT administered to an individual patient at the first administration within each treatment block is selected from about 1 mg to about 2 mg, and then increased with each subsequent administration within each treatment block until reaching 10 mg, or the earlier of all administrations within that treatment block.

[0155] In an even more preferred embodiment, the dose of 5-MeO-DMT administered to an individual patient at the first administration within each treatment block is selected from about 1 mg to about 2 mg, and then increased with each subsequent administration within each treatment block until the earlier of: reaching 10 mg, or all administrations within the treatment block have been administered, or the patient has experienced a peak psychedelic experience, or the attending physician determines that it is not appropriate to further increase the dose based on observed side effects.

[0156] For embodiments involving subsequent dose increases, the dose of the next administration is determined by adding about 0.25 mg to about 3 mg, preferably about 0.5 mg to about 3 mg, to the dose of the previous administration. For example, if the first administration dose was 1 mg and the dose is increased to 3 mg, the second administration dose is 4 mg unless one of the aforementioned discontinuation criteria has been met. Preferably, the third administration dose is 7 mg.

[0157] In a preferred embodiment, the dose of 5-MeO-DMT administered to an individual patient in each treatment block is selected from about 1 mg to about 3 mg at the first administration, and then increased to a dose selected from about 4 mg to about 6 mg at the second administration, and to a dose selected from about 7 mg to about 9 mg at the third administration, unless the patient has experienced a peak psychedelic experience in said treatment block or the attending physician determines that further dose increases are not appropriate based on observed side effects. Useful specific amounts for the first, second, and third administrations are, for example, about 2 mg, about 5 mg, and about 8 mg.

[0158] In another preferred embodiment, the dose of 5-MeO-DMT administered to an individual patient in each treatment block is selected from about 0.5 mg to about 1.5 mg at the first administration, and then increased to a dose selected from about 1.5 mg to about 2.5 mg at the second administration, and to a dose selected from about 2.5 mg to about 3.5 mg at the third administration, unless the patient has already experienced a peak psychedelic experience in said treatment block or the attending physician determines that further dose increases are not appropriate based on observed side effects. The useful specific amounts for the first, second, and third administrations are, for example, about 1 mg, about 2 mg, and about 3 mg.

[0159] In a further preferred embodiment, the dose of 5-MeO-DMT administered to an individual patient at the first administration of the first treatment block is selected from about 1 mg to about 2 mg, and then increased with each subsequent administration within the first treatment block until the earlier of: reaching 10 mg, or all administrations within the treatment block have been administered, or the patient has experienced a peak psychedelic experience, or the attending physician determines, based on observed side effects, that further dose increases are not appropriate, wherein the highest dose in the first treatment block will be used as the dose for all subsequent treatment blocks and administrations within those subsequent treatment blocks. For example, if the highest dose in the first treatment block is 8 mg because the patient experienced a peak psychedelic experience at that dose, then the dose for all subsequent treatment blocks and administrations within those subsequent treatment blocks will be 8 mg.

[0160] In a particularly preferred embodiment, the dose of 5-MeO-DMT administered to an individual patient at the first administration of the first treatment block is selected from about 1 mg to about 3 mg. Then, unless the patient has already experienced a peak psychedelic experience within the treatment block or the attending physician determines, based on observed side effects, that further dose increases are not appropriate, the second administration of the first treatment block will be increased to a dose selected from about 4 mg to about 6 mg, and the third administration of the first treatment block will be increased to a dose selected from about 7 mg to about 9 mg. The highest dose in the first treatment block will be used for all subsequent treatment blocks and for administrations within those subsequent treatment blocks. Useful specific amounts for the first, second, and third administrations in the first treatment block are, for example, about 2 mg, about 5 mg, and about 8 mg.

[0161] In a particularly preferred embodiment, the dose of 5-MeO-DMT administered to an individual patient at the first administration of the first treatment block is selected from about 0.5 mg to about 1.5 mg. Then, unless the patient has already experienced a peak psychedelic experience within the treatment block or the attending physician determines, based on observed side effects, that further dose increases are not appropriate, the second administration of the first treatment block will be increased to a dose selected from about 1.5 mg to about 2.5 mg, and the third administration of the first treatment block will be increased to a dose selected from about 2.5 mg to about 3.5 mg, wherein the highest dose in the first treatment block will be used as the dose for all subsequent treatment blocks and for administrations within those subsequent treatment blocks. Useful specific amounts for the first, second, and third administrations in the first treatment block are, for example, about 1 mg, about 2 mg, and about 3 mg.

[0162] It should be understood that pharmaceutically acceptable salts of 5-MeO-DMT are preferred for all of the above-described dosing regimens, and assuming the use of equimolar amounts, the appropriate weight of the salt to be administered can be calculated based on the specified weight of the free base.

[0163] According to the present invention, 5-MeO-DMT is preferably not administered together with MAO inhibitors.

[0164] A patient’s “peak psychedelic experience” can be identified by achieving at least 60% of the highest possible score on each of the four subscales (mystery, positive emotion, transcendence of time and space, and ineffable) of the revised Mysterious Experience Questionnaire-30 (MEQ-30) with 30 items (mystery, positive emotion, transcendence of time and space, and ineffable). (As described in Barrett FS, J Psychopharmacol. 2015; 29(11):1182-90).

[0165] Whether a patient experiences a “peak psychedelic experience” can also be determined by achieving at least 60% of the highest possible score on the Ocean-like Boundless (OBN) dimension of the Altered Consciousness State (ASC) questionnaire (as described in Roseman L et al., Front Pharmacol. 2018; 8:974).

[0166] According to the present invention, whether a patient experiences a “peak psychedelic experience” is preferably identified by achieving a total score of at least 75 on the Peak Experience Scale (PES), also known as the Peak Psychedelic Experience Questionnaire (PPEQ), which calculates the average score of the patient’s responses to the following three questions from 0 to 100: 1. How intense was the experience; 2. How much was the loss of control; 3. How significant (i.e., profound and important) was the experience?

[0167] Treatment of anxiety

[0168] According to the present invention, anxiety in patients suffering from anxiety disorders or other mental or neurological disorders related to anxiety can be treated. Furthermore, anxiety in patients suffering from sleep disorders (e.g., insomnia) can be treated.

[0169] In patients suffering from anxiety associated with another mental disorder or neurological disorder or sleep disturbance (e.g., insomnia), the anxiety treatment according to the invention leads to improvement in the anxiety-related disorder.

[0170] The treatment according to the invention is performed by applying 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0171] Administration of 5-MeO-DMT to a patient disrupts established functional connectivity patterns within and / or between resting-state networks. This disruption leads to a reset of pathologically malfunctioning connections when the network reconnects. New, healthy functional connections are then established, and their effects are lasting.

[0172] Therefore, according to the present invention, influencing these networks through the therapy described herein will result in an improvement in anxiety, and if the treated patient suffers from another mental or neurological disorder related to anxiety, that disorder will also be improved; if the treated patient suffers from a sleep disorder, such as insomnia, that sleep disorder will also be improved.

[0173] To further support the clinical application of 5-MeO-DMT in patients suffering from anxiety, the inventors evaluated clinical data related to the use of 5-MeO-DMT in patients being treated for mental illness and noted a particular improvement in anxiety, which is also commonly observed in patients with other disorders.

[0174] This data comes from a recently completed clinical trial that used 5-MeO-DMT to treat patients diagnosed with treatment-resistant depression (TRD; see also the Examples section below). While TRD is a specific disorder, as discussed in detail below, the inventors determined that certain clinical observations made in the trial are relevant to the design of treatments for anxiety disorders and other anxiety-related disorders.

[0175] In clinical trials, 5-MeO-DMT was administered via inhalation (described in more detail in the Examples section below). Patients were assigned to different groups. In the context of this invention, it is of interest to receive a single 12 mg dose and to receive an intraday individualized dosing regimen (IDR) that allows for multiple dose increases (6 mg, 12 mg, and 18 mg) throughout the day based on the intensity of the patient's reported psychedelic experience.

[0176] The collected data included assessments of treated patients on several scales, including the Montgomery-Asperger Depression Rating Scale (MADRS) and the Brief Psychiatric Rating Scale (BPRS). While the trial focused on demonstrating therapeutic efficacy through improvements in overall MADRS scores, the inventors focused on the items that make up the various rating scales and noted that specific sub-rating items (such as those related to anxiety) were associated with other disorders in which anxiety was based on similarly altered functional connectivity within and / or between resting-state networks.

[0177] Multiple patients in the recruited cohort showed significant improvement, a result that confirms the inventors’ finding that 5-MeO-DMT is a suitable compound for treating patients with these symptoms.

[0178] More specifically, one aspect that can be treated by applying 5-MeO-DMT is anxiety. 5-MeO-DMT can be administered to patients to reduce or eliminate their anxiety.

[0179] The BPRS item that is particularly relevant in this context is "anxiety." This item is associated with reported worry, tension, fear, panic, or concern. Possible ratings are:

[0180] 1- No anxiety

[0181] 2 - Very mild. Reports some discomfort due to worry or infrequent worry, which occurs more frequently than in most normal individuals.

[0182] 3 - Mild. Frequent worry, but able to easily shift attention to other things.

[0183] 4- Moderate. Most of the time is spent in a state of worry and difficulty shifting attention to other things, but function is not impaired; or occasional anxiety occurs with autonomic symptoms, but function is not impaired.

[0184] 5 - Moderate to severe. Frequent (but not daily) anxiety, accompanied by autonomic symptoms, or disturbances in some functional areas due to anxiety or worry.

[0185] 6- Severe. Daily anxiety accompanied by autonomic symptoms, but not lasting all day, or many functional areas are disturbed due to anxiety or persistent worry.

[0186] 7 - Very severe. Anxiety accompanied by autonomic symptoms lasting all day, or most functional areas are disturbed due to anxiety or persistent worry.

[0187] In the study group receiving individualized dosing regimens, the total score for the BPRS item "anxiety" in all 8 patients was 37 at baseline.

[0188] Three hours later, the score dropped to 19, corresponding to an improvement of 18 points or 49%. On day 1 post-treatment, the score dropped to 16, corresponding to an improvement of 21 points or 57%. On day 7 post-treatment, the score dropped to 17, corresponding to an improvement of 20 points or 54%.

[0189] In the 12mg group, the total score of the BPRS item “anxiety” in all 4 patients was 25 at baseline.

[0190] Three hours later, the score dropped to 11, corresponding to a 14-point or 56% improvement. On day 1 post-treatment, the score dropped to 6, corresponding to a 19-point or 76% improvement. On day 7 post-treatment, the score dropped to 6, corresponding to a 19-point or 76% improvement.

[0191] The inventors concluded that 5-MeO-DMT can be used to treat anxiety in patients, such as those suffering from anxiety disorders and those suffering from mental or neurological disorders and related anxiety.

[0192] Therefore, according to the present invention, treatment of patients suffering from anxiety with 5-MeO-DMT or a pharmaceutically acceptable salt thereof reduces or eliminates anxiety.

[0193] The MADRS program defines "inner tension" as vague feelings of discomfort, anxiety, inner turmoil, or heightened anxiety that can escalate into panic, fear, or distress. It is assessed based on intensity, frequency, duration, and the required level of assurance.

[0194] A score of 0 is given if the patient is calm and experiences only brief periods of inner tension. A score of 2 is given if the patient occasionally feels agitated and experiences vague discomfort. A score of 4 is given if the patient experiences persistent inner tension or intermittent panic that is difficult to control. A score of 6 is given if the patient experiences persistent fear or distress and overwhelming panic.

[0195] In the trial involving TRD patients mentioned above, in the study group receiving individualized dosing, all 8 patients had a total MADRS score of 26 for "Inner Stress" at baseline. Two hours later, the score decreased to 11, corresponding to a 15-point or 58% improvement. On day 1 post-treatment, the score decreased to 6, corresponding to a 20-point or 77% improvement. On day 7 post-treatment, the score decreased to 12, corresponding to a 14-point or 54% improvement.

[0196] In the 12mg group, the total MADRS item "Inner Stress" score for all 4 patients was 13 at baseline. Two hours later, the score decreased to 2, corresponding to an 11-point or 85% improvement. On day 1 post-treatment, the score decreased to 3, corresponding to a 10-point or 77% improvement. On day 7 post-treatment, the score decreased to 5, corresponding to an 8-point or 62% improvement.

[0197] These results further support the inventors' conclusion that the treatment according to the invention reduces or eliminates the symptoms of anxiety.

[0198] The treatment according to the invention resulted in a clinical response in patients suffering from anxiety symptoms, reflected as a decrease of at least 50% in HAM-A score compared to the corresponding score before treatment approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28.

[0199] Clinical response (reflected by a decrease of at least 50% in HAM-A score compared to the corresponding pre-treatment score) in patients with anxiety symptoms occurs no later than about 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt. Clinical response (reflected by a decrease of at least 50% in HAM-A score) in patients with anxiety symptoms preferably persists for at least 6 days after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; particularly for at least 14 days after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; more preferably for at least 28 days after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt.

[0200] Relief of anxiety symptoms in patients with anxiety symptoms was reflected in a HAM-A score of 7 or lower approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0201] For patients with anxiety symptoms, relief of anxiety symptoms (reflected by a HAM-A score of 7 or lower) occurs no later than approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. Relief of anxiety symptoms (reflected by a HAM-A score of 7 or lower) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0202] Therefore, according to the present invention, treatment of patients suffering from anxiety with 5-MeO-DMT or a pharmaceutically acceptable salt thereof reduces or eliminates anxiety.

[0203] Anxiety and Sleep

[0204] Sleep disorders are conditions that affect the quality, duration, or duration of sleep, whether idiopathic or occurring within the context of a medical condition (e.g., a mental disorder, a neurological disorder, or a medical condition that leads to a related mental or neurological disorder). Sleep disorders can impair a person's ability to function normally while awake, particularly by impairing cognitive function and causing anxiety.

[0205] There are two basic types of sleep: rapid eye movement (REM) sleep and non-REM sleep. Non-REM sleep can be divided into four stages (I-IV). These non-REM stages correspond to increases in sleep depth. During the four to five cycles of normal human sleep each night, non-REM and REM sleep alternate. In the earlier part of the night, non-REM sleep is deeper and takes up a disproportionately large amount of time, especially in the first sleep cycle. As the night progresses, non-REM sleep becomes shallower, and more time in each cycle is allocated to REM sleep.

[0206] Normal, healthy sleep consists of different stages as described above, which occur in a continuous, strictly controlled sequence throughout the night.

[0207] Such strict interruption of control can lead to sleep disorders.

[0208] Common forms of sleep disorders include difficulties in falling asleep and maintaining sleep (insomnia), excessive sleepiness (hypersomnia), sleep-wake cycle disorders (circadian rhythm disorders), functional disorders related to sleep, sleep stages or partial awakening (parasomnia), disorders characterized by breathing disturbances during sleep (sleep-related breathing disorders), and disorders characterized by abnormal movements during sleep (sleep-related motor disorders).

[0209] Insomnia is a sleep disorder in which patients have difficulty falling asleep or maintaining sleep. Symptoms of insomnia include difficulty falling asleep; frequent awakenings during the night and difficulty falling back asleep; waking up too early in the morning; poor sleep quality; and / or having at least one daytime problem due to poor sleep quality, such as fatigue, drowsiness, mood problems, poor concentration, accidents at work or while driving, etc.

[0210] Excessive sleepiness is characterized by excessive daytime sleepiness and / or prolonged nighttime sleep duration. Sleep intoxication is also a symptom found in patients with excessive sleepiness. The transition from sleep to wakefulness is very difficult. Individuals who have experienced sleep intoxication report feeling confused, disoriented, sluggish, and experiencing recurrent sleep episodes upon waking.

[0211] Circadian rhythm disorders are characterized by chronic or recurrent sleep disturbances resulting from alterations in an individual's internal circadian rhythm or from inconsistencies between their circadian rhythm and their desired or needed work or social schedules. This asynchrony may be temporary or persistent. Subsequent clinical presentations combine symptoms of insomnia and hypersomnia. Sleep duration is typically shortened and interrupted, performance in the desired awake state is impaired, and a temporary inability to restore a normal sleep schedule is observed.

[0212] Parasomnias refer to various forms of sleep disorders characterized by unusual behavioral or physiological activities (such as sleepwalking or nightmares) experienced before falling asleep, during sleep, or during the wakefulness period between sleep and wakefulness. They vary considerably in characteristics, severity, and frequency. Parasomnias can impair sleep quality.

[0213] Sleep-related breathing disorders are characterized by abnormal and difficult breathing during sleep. Breathing is a complex process that relies heavily on the coordinated action of respiratory muscles and the brain (the control center). One form of sleep-related breathing disorder is central sleep apnea. This occurs, for example, when the brain stops sending signals to control breathing based on an underlying health condition. Central sleep apnea has potentially serious effects on sleep and the balance of oxygen and carbon dioxide in the blood. Reduced airflow leads to intermittent hypoxia, resulting in fragmented sleep due to micro-awakening or wakefulness. The consequence can be excessive daytime sleepiness.

[0214] Among sleep-related movement disorders, repetitive, relatively simple, and often stereotyped movements can interfere with sleep or the onset of sleep. The most common of these are restless legs syndrome (RLS) and periodic limb tic disorder (PLMD).

[0215] Insufficient sleep duration or quality may lead to personality changes and may not only exacerbate existing mental illnesses but also become a trigger for their development.

[0216] Sleep disorders (such as insomnia) are highly comorbid with anxiety disorders. Insomnia and anxiety may be mutually influential, as insomnia often precedes anxiety, but anxiety symptoms are associated with abnormal sleep-wake cycles and can therefore lead to sleep disorders. For example, excessive worry and fear can make it harder to fall asleep and harder to stay asleep through the night.

[0217] Anxiety can affect the sleep cycle because anxiety and pre-sleep contemplation can disrupt rapid eye movement (REM) sleep, which is involved in the most vivid dreams. It can trigger more disturbing dreams, thus increasing the likelihood of sleep disruption.

[0218] Furthermore, the difficulty in falling asleep itself can complicate the problem, leading to sleep anxiety that intensifies feelings of fear and unease. These negative thoughts about sleep constitute a type of anticipatory anxiety, posing challenges to healthy sleep plans and daily routines.

[0219] Sleep deprivation can exacerbate anxiety, triggering a vicious cycle involving insomnia and anxiety.

[0220] The locus coeruleus-norepinephrine system (LC-NS) is a brainstem region crucial for arousal and attention. Its dysfunction is associated with insomnia and anxiety symptoms in patients with chronic insomnia.

[0221] Poor sleep quality has a significant impact on functional impairment. Compared to patients with anxiety disorders alone, patients with both anxiety disorders and sleep disorders have significantly worse mental health-related quality of life and higher disability rates.

[0222] Because of the bidirectional relationship between sleep disorders (primarily insomnia) and anxiety, sleep disorders are very common in patients with social anxiety disorder, agoraphobia, phobias, and substance / drug-induced anxiety disorders.

[0223] Separation anxiety disorder is also associated with sleep disturbances. In fact, sleep disturbances are part of the diagnostic criteria for separation anxiety disorder. Sleep disturbances in patients with separation anxiety disorder include nightmares, difficulty falling asleep or staying asleep, early awakening, and parasomnias.

[0224] Sleep disturbances (particularly including difficulty falling asleep or maintaining sleep, or restless and unsatisfactory sleep) are a key feature of generalized anxiety disorder (GAD). Sleep disturbances are associated with a significant disability rate in GAD. In the DSM-5 criteria, sleep disturbance is one of six symptoms, and at least three of these symptoms must be present for a period of time to meet the diagnostic criteria for GAD.

[0225] Sleep disturbances (particularly insomnia and hypersomnia) are very common in patients with panic disorder. Individuals with panic disorder may also experience nocturnal panic attacks, which are different from night terrors. Nocturnal panic attacks can occur without any trigger and often make it difficult to fall back asleep.

[0226] Treatment for sleep disorders varies depending on the type and underlying cause. Maintaining good sleep hygiene, a healthy sleep environment, and a consistent sleep-wake schedule are often considered first-line treatments. If these are unsuccessful, treatment may involve medication or psychotherapy.

[0227] The available treatments were unsuccessful in all patients, possibly due to side effects and / or the need for long-term treatment to achieve the desired therapeutic effect.

[0228] In patients with sleep disorders associated with mental or neurological disorders, known treatments for the mental or neurological disorders do not necessarily improve the sleep disorder.

[0229] For example, sleep disorders are frequently associated with mental illnesses such as depression. However, treating depression does not necessarily lead to an improvement in the accompanying sleep disorder. While most antidepressants have been shown to affect sleep structure, some classes of antidepressants improve sleep, while others may cause sleep impairment.

[0230] To assess sleep, parameters such as sleep duration, sleep structure, sleep latency, and the frequency and duration of wakefulness throughout the night can be measured. Quantitative indicators can be measured using objective methods, including polysomnography, actigraphy, and determination of sleep latency, or through self-report measurements (questionnaires).

[0231] Polysomnography is a technique that requires overnight monitoring of patients in a specialist clinic. Various functions are measured throughout the night, including eye movements, brain and muscle activity, breathing effort and airflow, blood oxygen levels, body posture and movement, snoring, and heart rate.

[0232] Another quantitative measurement is a wrist angiography. A wrist angiography sensor is worn to measure motor activity, which is continuously recorded and used to assess the sleep-wake cycle. This technology allows patients to continue their normal lives while recording the necessary data in a natural sleep environment.

[0233] Sleep latency can be measured using the Multiple Sleep Latency Test (MSLT). This test provides an objective measure of how long it takes for a person to fall asleep after multiple naps. An average sleep latency of approximately 10 minutes is considered normal; less than 8 minutes indicates sleep disturbance / excessive daytime sleepiness. Accompanying brain activity analysis can help in further diagnosing sleep disturbances.

[0234] The sleep assessment questionnaire recorded the evaluation of components of sleep quality, such as perceived sleep depth, difficulty of awakening, and rest after sleep, as well as other factors that may affect sleep quality, such as comorbidities and medication use. Since anxiety is associated with sleep disorders, anxiety can be included as part of the assessment.

[0235] Qualitative evaluation of the sleep experience is very important because sleep discomfort may persist even if quantitative sleep measurements are normal.

[0236] Questionnaires not only help to quickly and accurately assess complex clinical problems, but they can also help track patient progression. Therefore, patient-completed self-reported sleep questionnaires are an important basis for assessing sleep disorders in clinical practice.

[0237] Various sleep quality indices are known. The following indices include examples of questionnaires assessing general sleep, as well as examples of questionnaires specifically assessing insomnia, excessive sleep, circadian rhythm disorders, and parasomnias. However, this invention is not limited to using specific indices or questionnaires.

[0238] Some questionnaires rely on a recall period (recall window) of several days or even weeks. While this may be suitable for diagnosing sleep disorders, it is not always appropriate for assessing treatment effectiveness, especially for treatments with a rapid onset of action. For some questionnaires, the recall period can be modified so that the obtained scores reflect a period of time after treatment. This article specifically discusses questionnaires assessing the sleep effects of treatment on patients with specific disorders, which rely on a recall period that begins no earlier than the time of resolution of the acute psychedelic experience following the last administration. To meet this criterion, the recall period for normal application should be modified if necessary.

[0239] For example, the Sleep Quality Scale (SQS) and the Sleep-50 Questionnaire can be used to assess general sleep quality.

[0240] The Sleep Quality Scale (SQS) is a comprehensive assessment tool that provides a universal and efficient measure of sleep quality suitable for evaluating a wide range of patient and research populations. Individual questions regarding daytime symptoms, such as attention problems, difficulty concentrating or memory problems (item 15 "Poor sleep quality makes it difficult to think," item 19 "Poor sleep quality causes me to make mistakes at work," item 21 "Poor sleep quality makes me more forgetful," item 22 "Poor sleep quality makes it difficult to concentrate at work"), recovery after sleep, problems falling asleep and maintaining sleep, difficulty waking up, and sleep satisfaction, can be rated from 0 ("rarely") to 3 ("almost always"), with higher scores indicating more severe sleep problems (A. Shahid et al. (eds.), STOP, THAT and One Hundred Other Sleep Scales, Springer Science + Business Media, LLC 2012). Respondents are asked to report their experiences from the previous month or another appropriate window of memory.

[0241] A decrease in the score indicates successful treatment.

[0242] The Sleep-50 Questionnaire consists of 50 items and is designed to screen the general population for various types of sleep disorders. The scale comprises nine subscales reflecting some of the most common sleep-related disorders and discomforts associated with factors required for diagnosis, such as sleep apnea, insomnia, narcolepsy, restless legs / periodic leg movement disorder, circadian rhythm sleep disorder, sleepwalking, nightmares, factors affecting sleep, and the impact of sleep discomfort on daily functioning. For each item, respondents are given a scale from 1 (“none”) to 4 (“a lot”) and are asked to indicate how well the statement matches their experience in the previous month or another appropriate recall window.

[0243] In order to diagnose sleep disorders, not only must a specific subscale (e.g., insomnia) exceed a certain cutoff point, but respondents must also reach at least 3 or 4 ("quite a lot" or "very a lot") cutoff points on a subscale that assesses the impact of sleep discomfort on daily functioning (Spoormaker et al. Initial validation of the SLEEP-50 questionnaire. Behav Sleep Med. 2005; 3(4):227-46).

[0244] Treatment success is indicated by (i) a decrease in the score, preferably (ii) a decrease in the score below the cutoff value.

[0245] The Pittsburgh Sleep Quality Index is a commonly used questionnaire for assessing sleep disorders. Other tools include the Insomnia Severity Index, the Espie Sleep Disorder Questionnaire, and the Patient Reported Outcomes Measurement Information System. Sleep disorders.

[0246] The Pittsburgh Sleep Quality Index (PSQI) assesses overall sleep quality and sleep disturbances. The PSQI is a self-assessment questionnaire containing 19 questions. Respondents are asked to indicate the frequency with which they experienced certain sleep difficulties in the past month or another appropriate memory window.

[0247] Nineteen self-assessment questions assessed a variety of factors associated with sleep quality, including estimates of sleep duration and latency, as well as estimates of the frequency and severity of specific sleep-related problems. These 19 items were divided into seven components: (1) subjective sleep quality; (2) sleep latency; (3) sleep duration; (4) habitual sleep efficiency; (5) sleep disturbances; (6) use of sleeping pills; and (7) daytime dysfunction.

[0248] Each component is scored from 0 to 3. The higher the score, the more severe the sleep disorder. Detailed scoring instructions for the Pittsburgh Sleep Quality Index can be found in the appendix of Buysse et al., The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May; 28(2): 193-213.

[0249] The scores of the seven components are then summed to obtain an overall score, ranging from 0 to 21, where "0" indicates no difficulty and "21" indicates severe difficulty in all areas. A total score cutoff of 5 distinguishes people with poor sleep quality from those with good sleep quality. A total score >5 indicates that the patient has severe difficulty in at least two areas, or moderate difficulty in more than three areas.

[0250] If the PSQI is used to assess treatment outcomes, treatment success is indicated by (i) a decrease in the score, preferably (ii) a decrease in the score to 5 or below.

[0251] The Insomnia Severity Index (ISI) is a short questionnaire that assesses subjective sleep quality, symptom severity, subjective satisfaction with sleep, the degree to which insomnia interferes with daily functioning (item 3, “To what extent do you feel your sleep problems interfere with your daily functioning (e.g., daytime fatigue, work / daytime routine functioning, concentration, memory, mood, etc.)”), how significantly the respondent feels their insomnia is compared to others, and the overall level of distress caused by the sleep problem. Individuals can rate their responses from 0 (= none) to 4 (= very); a higher total score corresponds to more severe insomnia. A total score of 0-7 indicates “no clinically significant insomnia,” 8-14 indicates “below-threshold insomnia,” 15-21 indicates “clinical insomnia (moderate severity),” and 22-28 indicates “clinical insomnia (moderate)” (A. Shahid et al., ibid.). The typical recall window for the ISI is two weeks, but other appropriate recall windows may also be used in this study.

[0252] Treatment success is indicated by (i) a decrease in score, for example, a decrease of >7 points, especially >8 points; preferably (ii) a decrease in score below the cutoff value for clinically significant insomnia.

[0253] The Espie Sleep Disorders Questionnaire (SDQ) assesses the subjective experience of insomnia. The SDQ rates anxiety / agitation, hyperactivity, consequences of insomnia, and inadequate sleep preparation, with a particular focus on beliefs about the root causes of sleep problems. Respondents use a five-point scale to indicate how frequently certain statements about insomnia represent their experiences. 1 indicates "never true," while 5 indicates "often true." Higher scores indicate more abnormal beliefs about the causes and related factors of insomnia (A. Shahid et al., ibid.).

[0254] A decrease in the score indicates successful treatment.

[0255] Patient Reported Outcome Information System The Sleep Disorder Tool is a common method for assessing sleep disorders. The tool consists of a long scale and four different short scales (e.g., four, six, and eight items), and assesses self-reported sleep quality, perceived sleep depth, and any perceived difficulties related to falling asleep and maintaining sleep over a seven-day period.

[0256] Each item in the measurement was assessed using a 5-point scale. The raw scores for each item were summed to obtain the total raw score. Then, a conversion table was used to convert the total raw score into a standardized T-score.

[0257] Successful treatment is indicated by a decrease in the T score.

[0258] Excessive sleep or hypersomnia can be assessed using the Epworth Sleepiness Scale, the Stanford Sleepiness Scale, or the Idiopathic Hypersomnia Severity Scale.

[0259] The Epworth Sleepiness Scale (ESS) assesses overall daytime sleepiness. The questionnaire asks respondents to rate their likelihood of falling asleep under eight different conditions, representing relatively inactive times such as an afternoon nap or sitting in a parked car. Respondents use a scale of 0-3 (0 meaning "never sleepy" and 3 meaning "very likely to sleepy") to rate their likelihood of falling asleep. The rating ranges from 0-24; higher ratings indicate greater severity of daytime sleepiness. A cutoff score of 10 indicates a possible clinical presentation of daytime sleepiness (A. Shahid et al., ibid.).

[0260] Treatment success is indicated by (i) a decrease in the score, preferably (ii) a decrease in the score to 10 or below.

[0261] The Stanford Somnolence Scale is a subjective measure of sleepiness that assesses the level of sleepiness at a given moment. The scale consists of only one item, requiring respondents to choose one of seven statements that best represents their current perceived level of sleepiness. Sleepiness is assessed using a scale ranging from 1 (= feeling active and energetic; alert; fully awake) to 7 (= almost hallucinating; falling asleep quickly; unable to stay awake) (A. Shahid et al., ibid.).

[0262] A decrease in the score indicates successful treatment.

[0263] Parasomnias can be assessed using the Paris Arousal Disorders Severity Scale (PADSS).

[0264] The Paris Arousal Disorders Severity Scale (PADSS) is a self-rating scale that lists parasomnia behaviors, assesses the frequency of parasomnia behaviors, and includes evaluations of consequences (Arnulf et al. A scale for assessing the severity of arousal disorders. Sleep. 1 Jan 2014; 37(1):127-36).

[0265] Treatment success is indicated by (i) a decrease in the score, preferably (ii) a decrease in the score below the cutoff value.

[0266] A commonly used questionnaire for assessing sleep-related breathing disorders is the Berlin Questionnaire (A. Shahid et al., ibid.). An appropriate recall period can also be selected.

[0267] A decrease in the score indicates successful treatment.

[0268] A commonly used questionnaire for assessing sleep-related movement disorders is the International Restless Legs Syndrome Study Group Rating Scale. The 10-item questionnaire requires respondents to use Likert rating to indicate how severe the disorder has been for them over the past week. Questions are divided into two categories: symptoms of the disorder (nature, intensity, and frequency) and their impact (sleep problems, disruption of daily functioning, and resulting mood changes). Each of the ten questions requires respondents to rate their experience of RLS on a scale of 0 to 4, where 4 represents the most severe and frequent symptoms, and 0 represents the fewest symptoms. The total score can range from 0 to 40. As a concise scale with excellent psychometric quality, this tool is suitable for a variety of research and clinical purposes, including screening and evaluating treatment outcomes. (A. Shahid et al., ibid.)

[0269] A decrease in the score can be used to assess the treatment response.

[0270] Treatment response can be evaluated using the quantitative measurements described above (such as polysomnography or wrist movement) and / or the questionnaires described above. A significant decrease or increase in the total score, or a significant reduction in the prevalence, frequency, or impact on daily functioning, according to the corresponding sleep scale, indicates improvement in treatment-induced sleep disturbances.

[0271] The severity of anxiety can be assessed using the 14-item Hamilton Anxiety Rating Scale (HAM-A), with sleep disturbance assessment being an integral part of the scale. Item 4, "Insomnia," is defined as "difficulty falling asleep, interrupted sleep, unsatisfactory sleep and fatigue upon waking, dreaming, nightmares, and night terrors." Each item is rated on a scale from 0 (absent) to 4 (severe).

[0272] To enhance our understanding of pathophysiology and underlying compensatory mechanisms, resting-state fMRI has been widely used in patients with sleep disorders.

[0273] Alterations in the resting state network can be found in insomnia, excessive sleep, circadian rhythm disorders, parasomnias, sleep-related breathing disorders, and sleep-related motor disorders.

[0274] In insomnia patients, functional connectivity impairments have been observed within the default mode network (DMN) and the salience network, which are associated with the detection and integration of emotional and sensory stimuli. Research indicates that these networks contain key areas for integrating emotional and physical states, and impaired functional connectivity between these networks and other brain regions, both internally and / or externally, may be a contributing factor to patients' alertness, subjective distress, and poor sleep continuity.

[0275] For example, sleep deprivation in healthy subjects leads to changes in functional connectivity within and / or between the default mode network, dorsal attention network, and salience network, and these changes in brain functional connectivity are somewhat similar to the vulnerability pattern in Alzheimer's patients.

[0276] In patients with excessive sleep, the default mode network is affected. For example, in idiopathic excessive sleep, different DMN centers (precuneus and medial prefrontal cortex) show significant changes, and functional connectivity in the DMN is associated with the severity of self-reported sleepiness.

[0277] A study investigating differences between night-shift and day-shift nurses revealed that circadian rhythm disturbances promote changes in resting-state function in the cerebellum, involving sleep regulation and cognitive functions such as responsiveness and alertness. Furthermore, functional connectivity in the DMN differs fundamentally between early and late circadian rhythm phenotypes. Like other forms of sleep disorders, circadian rhythm disturbances lead to alterations in brain functional connectivity. Changes in resting-state brain functional connectivity have been reported in various disorders involving circadian rhythm disturbances.

[0278] Although performing functional brain imaging during parasomnia events is technically difficult, differences in the precuneus have been observed in arousal disorders that represent non-REM parasomnia.

[0279] The precuneus is involved in the analysis and integration of visual, auditory, and somatosensory information, as well as the monitoring of movement. The precuneus is a subregion of the DMN. Therefore, the default mode network is affected in patients with parasomnias.

[0280] Resting-state fMRI studies in patients with sleep-related breathing disorders, such as central sleep apnea, revealed severe global and regional connectivity deficits, particularly in the default mode network (DMN) and in areas involved in arousal and sensorimotor systems. Sleep-related motor disorders, such as periodic limb movements during sleep, were reflected by alterations in the prefrontal motor control pathway (a subregion of the default mode network). Furthermore, activity was observed in the cerebellum and thalamus, as well as additional activation in the red nucleus and brainstem.

[0281] In many cases, the resting-state networks involved in sleep regulation are also involved in cognition. Therefore, according to the present invention, influencing these networks through the therapy according to the present invention will lead to an improvement in sleep disorders, and if the treated patient suffers from anxiety, it will also lead to an improvement in anxiety.

[0282] Clinical data from studies on patients with treatment-resistant depression (TRD) or postpartum depression (PPD) have demonstrated that sleep disorders can be successfully treated with 5-MeO-DMT.

[0283] In the TRD study, which is described in more detail in the Examples section below, among other things, the MADRS item “Sleep Reduction”, which reflects insomnia, was evaluated.

[0284] The MADRS program's "reduced sleep" rating represents a decrease in sleep duration or depth compared to a participant's normal sleep pattern when they are healthy. A score of 0.2 indicates mild difficulty falling asleep, or slightly reduced, shallower, or more fragmented sleep. A score of 4 indicates a reduction or interruption of at least two hours of sleep. A score of 6 indicates less than two or three hours of sleep.

[0285] In the study group receiving the individualized dosing regimen, all eight patients had a total MADRS score of 25 for “reduced sleep” at baseline. On day 1 post-treatment, the earliest time point for assessing the treatment’s effect on sleep, the score decreased to 12, corresponding to a 13-point or 52% improvement. On day 7 post-treatment, the score decreased to 9, corresponding to a 16-point or 64% improvement.

[0286] In the 12mg group, all four patients had a total MADRS score of 12 for “reduced sleep” at baseline. On day 1 after treatment, the score decreased to 10, corresponding to a 2-point or 17% improvement. On day 7 after treatment, the score decreased to 6, corresponding to a 6-point or 50% improvement.

[0287] Therefore, the score for "reduced sleep," a scale item particularly associated with sleep disorders, showed significant improvement. The inventors concluded that 5-MeO-DMT can be used to treat sleep disorders, especially in patients suffering from mental or neurological disorders.

[0288] Treatment of patients with sleep disorders (especially insomnia) and related anxiety with 5-MeO-DMT or its pharmaceutically acceptable salts reduced or eliminated anxiety and led to improvements in sleep disorders (especially insomnia).

[0289] Anxiety reduction or elimination was observed in patients with sleep disorders (particularly insomnia) approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0290] The reduction or elimination of anxiety in patients suffering from sleep disorders (especially insomnia) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt. The reduction or elimination of anxiety preferably continues for at least 6 days after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; particularly for at least 14 days after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; more preferably for at least 28 days after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt.

[0291] As mentioned above, anxiety is a significant aspect of sleep disorders. Therefore, improvements in anxiety can also lead to improvements in sleep disorders. Since anxiety also affects other aspects of sleep disorders, the inventors concluded that the observed improvement in anxiety will further contribute to the overall improvement of sleep disorders (especially insomnia).

[0292] In cases of idiopathic sleep disorder, clinical response may be reflected by a decrease in the Clinical Global Impression-Severity (CGI-S) score. According to the invention, a decrease in the CGI-S score means a reduction of at least 1 point. Preferably, the CGI-S score is reduced by at least 2 points and / or drops to 0. Particularly preferably, the CGI-S score is reduced by at least 3 points and / or drops to 0.

[0293] Improvements in idiopathic sleep disorder were observed on day 1, e.g., approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; day 7; day 14; and / or day 28, reflected in a decrease in CGI-S score.

[0294] Improvement in idiopathic sleep disorder (reflected in a decrease in CGI-S score) occurred no later than approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0295] Improvement in idiopathic sleep disorder (reflected by a decrease in CGI-S score) preferably continues for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0296] In the case of idiopathic sleep disorder, improvement in sleep disorder (reflected at least by a “significant improvement” score on the Clinical Global Impression-Improvement (CGI-I) or Patient Global Impression-Improvement (PGI-I) scale) preferably occurs no later than about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0297] In the case of idiopathic sleep disorder, improvement in sleep disorder (reflected at least as a reduction in the “significant improvement” score in the CGI-I or PGI-I scores) preferably continues for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0298] Improvement in sleep disorders can also be assessed using any other scale that reflects changes in sleep quality or quantity, as described above, such as the Pittsburgh Sleep Quality Index (PSQI).

[0299] If the PSQI is used to assess treatment outcomes, treatment success is indicated by (i) a decrease in the score, preferably (ii) a decrease in the score to 5 or below.

[0300] Improvement in sleep disturbances (reflected by a decrease in the PSQI score, particularly to 5 or below) preferably occurs no later than about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, wherein the onset of the recall period is no earlier than the time point between the end of the acute psychedelic experience following the last administration and the assessment time point.

[0301] Improvement in sleep disturbance (reflected by a decrease in PSQI score) preferably continues for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof, wherein the start of the recall period is no earlier than the time point from the time of resolution of the acute psychedelic experience following the last administration to the assessment time point.

[0302] Improvement in sleep disturbances (reflected as a decrease in PSQI score) was observed on day 1, e.g., approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; day 7; day 14; and / or day 28, where the onset of the recall period was no earlier than the time point from the time of resolution of the acute psychedelic experience following the last administration to the assessment time point.

[0303] Anxiety and sleep disorders (especially insomnia) are closely associated with mental and neurological disorders. Both anxiety and sleep disorders (especially insomnia) can occur within mental or neurological disorders such as illnesses characterized by depressive episodes, such as major depressive disorder (MDD), postpartum depression (PPD), persistent depressive disorder, seasonal affective disorder, and bipolar disorder (BD), such as bipolar I and bipolar II; anxiety disorders, such as separation anxiety disorder, agoraphobia, generalized anxiety disorder (GAD), social anxiety disorder (SAD), panic disorder, and phobias, as well as substance / drug-induced anxiety disorders; somatic symptom disorders; obsessive-compulsive disorder and related disorders, such as obsessive-compulsive disorder (OCD) and body dysmorphic disorder (BDD); and somatic symptom disorders, such as body dysmorphic disorder. Disorders such as: BDD; obsessive-compulsive disorder (OCD); post-traumatic stress disorder (PTSD); pain disorders, such as chronic pain and fibromyalgia, and migraines; mental and behavioral disorders due to the use of psychoactive substances, such as substance use disorder (SUD); psychotic disorders, such as schizophrenia; Parkinson's disease; or schizotypal personality disorder; dementia, such as Alzheimer's dementia (AD), Parkinson's dementia (PDD), Lewy body dementia, vascular dementia, frontotemporal dementia; Parkinson's disease (PD); eating disorders; attention deficit hyperactivity disorder (ADHD); personality disorders, such as schizotypal personality disorder and borderline personality disorder; autism spectrum disorders; chronic fatigue syndrome.

[0304] Anxiety and sleep disorders (especially insomnia) can also occur in medical conditions that lead to related mental or neurological disorders, such as HIV, traumatic brain injury, or the sequelae of COVID.

[0305] The treatment according to the invention will result in improvement of anxiety and sleep disorders (especially insomnia), as well as improvement of related mental or neurological disorders, examples of which are listed above, and will also result in improvement of mental or neurological disorders related to certain medical health conditions as explained above.

[0306] Treatment of anxiety and mental and neurological disorders

[0307] Disorders characterized by depressive episodes

[0308] Several disorders are characterized by depressive episodes.

[0309] A depressive episode is a period of time characterized by depressed mood and / or loss of interest in most activities.

[0310] For example, according to DSM-V, a major depressive episode is characterized by the presence of five or more symptoms within the same two weeks, and the symptoms represent changes in function compared to the previous period; at least one of the symptoms is (1) depressed mood or (2) loss of interest or pleasure.

[0311] Patients with disorders characterized by depressive episodes may have a treatment-resistant form of the disorder.

[0312] Patients with disorders characterized by depressive episodes may also exhibit anxiety symptoms but are not diagnosed with an anxiety disorder (subthreshold anxiety).

[0313] The term “subthreshold anxiety” as used in this article specifically refers to a patient’s Hamilton Anxiety Rating Scale (HAM-A) score of at least 9 but less than 18, and / or a Beck Anxiety Scale (BAI) score of at least 11 but less than 16.

[0314] The patient may also be diagnosed with a disorder characterized by depressive episodes and an anxiety disorder, i.e., be considered to have comorbidity of the aforementioned disorders and anxiety. Such a patient may have a HAM-A score of at least 18 and / or a BAI score of at least 16.

[0315] Anxiety symptoms in patients with disorders characterized by depressive episodes (such as patients with the aforementioned disorder and subthreshold anxiety, or patients with a comorbidity of the aforementioned disorder and anxiety) are associated with more severe depression and an increased incidence of suicidal ideation.

[0316] The following scales can be used to assess anxiety in patients with disorders characterized by depressive episodes: Hamilton Anxiety Rating Scale (HAM-A); HAM-A Mental Anxiety Subscale (items 1-6 and 14 in total); HAM-A Anxiety Mood Item (item 1); Beck Anxiety Scale (BAI); Hamilton Depression Rating Scale (HAM-D) Anxiety / Somatization Factors (item total: Anxiety (Mental), Anxiety (Physical), Somatic Symptoms (Gastrointestinal), Somatic Symptoms (General), Hypochondriasis, and Insight); HAM-D item “Mental Anxiety” and / or “Physical Anxiety”; Montgomery-Asperger Depression Rating Scale (MADRS) item “Inner Tension”; Brief Psychiatric Rating Scale (BPRS) item “Anxiety”.

[0317] Suicidal ideation can be assessed using the MADRS Project's "Suicidal Thoughts" or the Columbia Suicide Severity Rating Scale (C-SSRS).

[0318] In patients suffering from disorders characterized by depressive episodes, altered functional connectivity has been observed within and / or between several brain regions associated with processing, regulation, emotional memory, rumination-related cognitive processes, impaired concentration, and physiological arousal. Anxiety also involves aberrant connectivity within and / or between resting-state networks (such as the default mode network and the salience network). These aberrant connections can be normalized through treatments according to the present invention.

[0319] Treatment of patients with a disorder characterized by depressive episodes (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with the disorder and subthreshold anxiety, or patients with a comorbidity of the disorder and anxiety) using 5-MeO-DMT or a pharmaceutically acceptable salt thereof reduced or eliminated anxiety and led to improvement of the disorder.

[0320] Anxiety reduction or elimination was observed in patients with disorders characterized by depressive episodes (including treatment-resistant forms of said disorders) such as patients with said disorder and subthreshold anxiety, or patients with comorbid said disorder and anxiety, approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28.

[0321] For patients suffering from a disorder characterized by depressive episodes (including treatment-resistant forms of said disorder) and experiencing anxiety symptoms (such as patients with said disorder and subthreshold anxiety, or patients with comorbidities of said disorder and anxiety), the reduction or elimination of anxiety occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0322] Anxiety reduction or elimination (reflected as a decrease in HAM-A score) was observed in patients with a disorder characterized by depressive episodes (including treatment-resistant forms of said disorder) and anxiety symptoms (such as patients with said disorder and subthreshold anxiety, or patients with comorbidities of said disorder and anxiety) at approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28.

[0323] For patients with a disorder characterized by depressive episodes (including treatment-resistant forms of said disorder) and anxiety symptoms (such as patients with said disorder and subthreshold anxiety, or patients with comorbidities of said disorder and anxiety), the reduction or elimination of anxiety (reflected by a decrease in HAM-A score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. The reduction or elimination of anxiety (reflected by a decrease in HAM-A score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0324] At approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, for example, approximately 24 hours later; on day 7; on day 14; and / or on day 28, a reduction or elimination of anxiety was observed in patients with a disorder characterized by depressive episodes (including treatment-resistant forms of said disorder) and anxiety symptoms (such as patients with said disorder and subthreshold anxiety, or patients with a comorbidity of said disorder and anxiety) (reflected as a decrease in the score of the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14).

[0325] For patients suffering from a disorder characterized by depressive episodes (including treatment-resistant forms of said disorder) and experiencing anxiety symptoms (such as patients with said disorder and subthreshold anxiety, or patients with a comorbidity of said disorder and anxiety), the reduction or elimination of anxiety (reflected by a decrease in the score of the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14)) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. The reduction or elimination of anxiety (reflected by a decrease in the score of the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14)) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0326] At approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, for example, approximately 24 hours later; on day 7; on day 14; and / or on day 28, a reduction or elimination of anxiety was observed in patients with a disorder characterized by depressive episodes (including treatment-resistant forms of said disorder) and anxiety symptoms (such as patients with said disorder and subthreshold anxiety, or patients with comorbidity of said disorder and anxiety) (reflected by a decrease in the score of the HAM-A Anxiety Item (Item 1).

[0327] For patients suffering from a disorder characterized by depressive episodes (including treatment-resistant forms of said disorder) and experiencing anxiety symptoms (such as patients with said disorder and subthreshold anxiety, or patients with a comorbidity of said disorder and anxiety), the reduction or elimination of anxiety (reflected by a decrease in the HAM-A anxiety item (Item 1) score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. The reduction or elimination of anxiety (reflected by a decrease in the HAM-A anxiety item (Item 1) score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0328] At approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, for example, approximately 24 hours later; on day 7; on day 14; and / or on day 28, a reduction or elimination of anxiety was observed in patients with disorders characterized by depressive episodes (including treatment-resistant forms of said disorders) such as patients with said disorder and subthreshold anxiety, or patients with comorbidities of said disorder and anxiety (reflected as a decrease in anxiety / somatic factors on the Hamilton Depression Rating Scale (HAM-D)).

[0329] For patients suffering from a disorder characterized by depressive episodes (including treatment-resistant forms of said disorder) and experiencing anxiety symptoms (such as patients with said disorder and subthreshold anxiety, or patients with a comorbidity of said disorder and anxiety), the reduction or elimination of anxiety (reflected as a decrease in HAM-D anxiety / somatic factors) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. The reduction or elimination of anxiety (reflected as a decrease in HAM-D anxiety / somatic factors) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0330] At approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, for example, approximately 24 hours later; on day 7; on day 14; and / or on day 28, a reduction or elimination of anxiety was observed in patients with a disorder characterized by depressive episodes (including treatment-resistant forms of said disorder) and anxiety symptoms (such as patients with said disorder and subthreshold anxiety, or patients with comorbidity of said disorder and anxiety) (reflected by a decrease in the HAM-D item scores for “mental anxiety” and / or “physical anxiety”).

[0331] For patients suffering from a disorder characterized by depressive episodes (including treatment-resistant forms of said disorder) and experiencing anxiety symptoms (such as patients with said disorder and subthreshold anxiety, or patients with a comorbidity of said disorder and anxiety), the reduction or elimination of anxiety (reflected by a decrease in the HAM-D item “Mental Anxiety” and / or “Physical Anxiety” scores) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. The reduction or elimination of anxiety (reflected by a decrease in the HAM-D item “Mental Anxiety” and / or “Physical Anxiety” scores) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0332] At approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, for example, approximately 24 hours later; on day 7; on day 14; and / or on day 28, a reduction or elimination of anxiety was observed in patients with a disorder characterized by depressive episodes (including treatment-resistant forms of said disorder) and anxiety symptoms (such as patients with said disorder and subthreshold anxiety, or patients with comorbidity of said disorder and anxiety) (reflected in a decrease in the MADRS item “Inner Tension” score).

[0333] For patients with a disorder characterized by depressive episodes (including treatment-resistant forms of said disorder) and anxiety symptoms (such as patients with said disorder and subthreshold anxiety, or patients with comorbidities of said disorder and anxiety), the reduction or elimination of anxiety (reflected by a decrease in the MADRS item “Inner Tension” score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. The reduction or elimination of anxiety (reflected by a decrease in the MADRS item “Inner Tension” score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0334] At approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, for example, approximately 24 hours later; on day 7; on day 14; and / or on day 28, a reduction or elimination of anxiety was observed in patients with a disorder characterized by depressive episodes (including treatment-resistant forms of said disorder) and anxiety symptoms (such as patients with said disorder and subthreshold anxiety, or patients with comorbidity of said disorder and anxiety) (reflected by a decrease in the BPRS item “Anxiety” score).

[0335] For patients with a disorder characterized by depressive episodes (including treatment-resistant forms of said disorder) and anxiety symptoms (such as patients with said disorder and subthreshold anxiety, or patients with comorbidities of said disorder and anxiety), the reduction or elimination of anxiety (reflected by a decrease in the BPRS item “Anxiety” score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. The reduction or elimination of anxiety (reflected by a decrease in the BPRS item “Anxiety” score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0336] Clinical response in patients with disorders characterized by depressive episodes and subthreshold anxiety was reflected in a decrease of at least 50% in HAM-D score compared to the corresponding pre-treatment score at approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1 after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt, for example, approximately 24 hours later; on day 7; on day 14; and / or on day 28.

[0337] Clinical responses (reflected by a decrease of at least 50% in HAM-D scores compared to the corresponding pre-treatment scores and a decrease in HAM-A scores to 7 or lower) in patients with disorders characterized by depressive episodes and subthreshold anxiety occurred no later than approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt.

[0338] Clinical response (reflected by a decrease of at least 50% in HAM-D score and a decrease in HAM-A score to 7 or lower) in patients with disorders characterized by depressive episodes and subthreshold anxiety preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0339] Clinical response in patients with comorbid disorders characterized by depressive episodes and anxiety was reflected as a decrease in HAM-D score of at least 50% and a decrease in HAM-A score of at least 50% compared to the corresponding pre-treatment scores at approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, e.g., approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0340] Clinical response in patients with a comorbid disorder characterized by depressive episodes and anxiety (reflected by a decrease of at least 50% in HAM-D score and at least 50% in HAM-A score compared to the corresponding pre-treatment scores) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. Clinical response in patients with a comorbid disorder characterized by depressive episodes and anxiety (reflected by a decrease of at least 50% in HAM-D score and at least 50% in HAM-A score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0341] For patients with a disorder characterized by depressive episodes (including treatment-resistant forms of the disorder) and subthreshold anxiety, or patients with comorbidities of the disorder (including treatment-resistant forms) and anxiety, remission is reflected as a HAM-A score of 7 or lower and a HAM-D score of 7 or lower at approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28.

[0342] For patients with a disorder characterized by depressive episodes (including treatment-resistant forms of said disorder) and subthreshold anxiety, or patients with comorbidities of said disorder (including treatment-resistant forms) and anxiety, remission (reflected by a HAM-A score of 7 or lower and a HAM-D score of 7 or lower) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. Remission (reflected by a HAM-A score of 7 or lower and a HAM-D score of 7 or lower) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0343] Treatment with 5-MeO-DMT or its pharmaceutically acceptable salts reduced or eliminated suicidal ideation in patients with a disorder characterized by depressive episodes (including treatment-resistant forms of the disorder) and subthreshold anxiety, or in patients with a comorbid disorder (including treatment-resistant forms) and anxiety.

[0344] Lessening or elimination of suicidal ideation was observed in patients with a disorder characterized by depressive episodes (including treatment-resistant forms of the disorder) and subthreshold anxiety, or patients with comorbidities of the disorder (including treatment-resistant forms of the disorder) and anxiety, approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28 (reflected in a decrease in the MADRS program “Suicidal Ideation” score).

[0345] For patients with a disorder characterized by depressive episodes (including treatment-resistant forms of said disorder) and subthreshold anxiety, or patients with comorbidities of said disorder (including treatment-resistant forms) and anxiety, the reduction or elimination of suicidal ideation (reflected by a decrease in the MADRS “Suicidal Thoughts” score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. The reduction or elimination of suicidal ideation (reflected by a decrease in the MADRS “Suicidal Thoughts” score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0346] Major depressive disorder (MDD) is a mood disorder that causes persistent feelings of sadness and loss of interest. MDD affects a person's feelings, thoughts, and behaviors and can lead to a variety of emotional and physical problems.

[0347] Patients with MDD may develop a treatment-resistant form of the disorder.

[0348] Patients with MDD may also exhibit anxiety symptoms but are not diagnosed with an anxiety disorder (subthreshold anxiety). In the terminology used in this article, such patients suffer from anxiety-depressive disorder.

[0349] The term “subthreshold anxiety” as used in this article specifically refers to a patient’s Hamilton Anxiety Rating Scale (HAM-A) score of at least 9 but less than 18, and / or a Beck Anxiety Scale (BAI) score of at least 11 but less than 16.

[0350] The patient may also be diagnosed with MDD as well as anxiety disorder, meaning they are considered to have comorbid anxiety and depression (rather than anxiety-depression). Such patients may have a HAM-A score of at least 18 and / or a BAI score of at least 16.

[0351] Anxiety symptoms in patients with MDD (such as those with anxiety-depression or those with comorbid anxiety and depression) are associated with more severe depression and an increased incidence of suicidal ideation.

[0352] The following scales can be used to assess anxiety in patients with MDD: Hamilton Anxiety Rating Scale (HAM-A); HAM-A Mental Anxiety Subscale (items 1-6 and 14 in total); HAM-A Anxiety Mood Item (item 1); Beck Anxiety Scale (BAI); Hamilton Depression Rating Scale (HAM-D) Anxiety / Somatization Factors (item total: Anxiety (Mental), Anxiety (Physical), Somatic Symptoms (Gastrointestinal), Somatic Symptoms (General), Hypochondriasis, and Insight); HAM-D item “Mental Anxiety” and / or “Physical Anxiety”; Montgomery-Asperger Depression Rating Scale (MADRS) item “Inner Tension”; Brief Psychiatric Rating Scale (BPRS) item “Anxiety”.

[0353] Suicidal ideation can be assessed using the MADRS Project's "Suicidal Thoughts" or the Columbia Suicide Severity Rating Scale (C-SSRS).

[0354] In patients with MDD, dysfunctional connectivity impairments and modulations within and / or between multiple resting-state networks (including the DMN, salience network, executive control network, and limbic network) have been observed. These functional connections differ significantly from those observed in healthy controls. Anxiety also involves aberrant connectivity within and / or between resting-state networks (such as the default mode network and salience network). These aberrant connections can be normalized through treatments according to the present invention.

[0355] Treatment of patients with MDD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-depressive disorder, or patients with comorbid anxiety and MDD) using 5-MeO-DMT or its pharmaceutically acceptable salts reduced or eliminated anxiety and led to improvement in MDD.

[0356] Reduction or elimination of anxiety was observed in patients with MDD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-related depression or comorbid anxiety and MDD) at approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28.

[0357] For patients with MDD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-induced depression, or patients with comorbid anxiety and MDD), the reduction or elimination of anxiety occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0358] Anxiety reduction or elimination (reflected as a decrease in HAM-A score) was observed in patients with MDD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-depressive disorder or comorbid anxiety and MDD) approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0359] For patients with MDD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-related depression, or patients with comorbid anxiety and MDD), the reduction or elimination of anxiety (reflected by a decrease in the HAM-A score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. The reduction or elimination of anxiety (reflected by a decrease in the HAM-A score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0360] Anxiety reduction or elimination (reflected as a decrease in the score of the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14)) was observed in patients with MDD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-depressive disorder or comorbid anxiety and MDD) at approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0361] For patients with MDD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-related depression, or patients with comorbid anxiety and MDD), the reduction or elimination of anxiety (reflected by a decrease in the score of the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14)) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety (reflected by a decrease in the score of the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14)) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0362] Reduction or elimination of anxiety was observed in patients with MDD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-related depression or comorbid anxiety and MDD) at approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28 (reflected by a decrease in the score of the HAM-A Anxiety Item (Item 1)).

[0363] For patients with MDD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-induced depression, or patients with comorbid anxiety and MDD), the reduction or elimination of anxiety (reflected by a decrease in the HAM-A anxiety item (Item 1) score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety (reflected by a decrease in the HAM-A anxiety item (Item 1) score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0364] At approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, for example, approximately 24 hours later; on day 7; on day 14; and / or on day 28, a reduction or elimination of anxiety was observed in patients with MDD (including treatment-resistant forms of the aforementioned disorder) and anxiety symptoms (such as patients with anxiety-related depression, or patients with comorbid anxiety and MDD) (reflected as a decrease in anxiety / somatic factors on the Hamilton Depression Rating Scale (HAM-D)).

[0365] For patients with MDD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-induced depression, or patients with comorbid anxiety and MDD), the reduction or elimination of anxiety (reflected as a decrease in HAM-D anxiety / somatic factors) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety (reflected as a decrease in HAM-D anxiety / somatic factors) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0366] Reduction or elimination of anxiety was observed in patients with MDD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-related depression or comorbid anxiety and MDD) at approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28 (reflected in a decrease in the HAM-D item scores for “mental anxiety” and / or “physical anxiety”).

[0367] For patients with MDD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-related depression, or patients with comorbid anxiety and MDD), the reduction or elimination of anxiety (reflected by a decrease in the HAM-D item scores for “mental anxiety” and / or “physical anxiety”) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety (reflected by a decrease in the HAM-D item scores for “mental anxiety” and / or “physical anxiety”) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0368] Anxiety reduction or elimination (reflected as a decrease in the MADRS item “Inner Tension” score) was observed in patients with MDD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-depressive disorder, or patients with comorbid anxiety and MDD) at approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0369] For patients with MDD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-related depression, or patients with comorbid anxiety and MDD), the reduction or elimination of anxiety (reflected by a decrease in the MADRS "Inner Tension" score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. The reduction or elimination of anxiety (reflected by a decrease in the MADRS "Inner Tension" score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0370] Reduction or elimination of anxiety (reflected as a decrease in the BPRS item “Anxiety” score) was observed in patients with MDD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-related depression, or patients with comorbid anxiety and MDD) at approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0371] For patients with MDD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-related depression, or patients with comorbid anxiety and MDD), the reduction or elimination of anxiety (reflected by a decrease in the BPRS item “Anxiety” score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety (reflected by a decrease in the BPRS item “Anxiety” score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0372] Clinical response in patients with anxiety-induced depression is reflected in a decrease of at least 50% in the HAM-D score compared to the corresponding pre-treatment score at approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1 after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt, for example, approximately 24 hours later; on day 7; on day 14; and / or on day 28.

[0373] Clinical response in patients with anxiety-induced depression (reflected by a decrease of at least 50% in the HAM-D score compared to the corresponding pre-treatment score, and a decrease in the HAM-A score to 7 or lower) occurs no later than approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. Clinical response in patients with anxiety-induced depression (reflected by a decrease of at least 50% in the HAM-D score, and a decrease in the HAM-A score to 7 or lower) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0374] Clinical response in patients with comorbid anxiety and MDD was defined as a reduction of at least 50% in HAM-D score and at least 50% in HAM-A score compared to the corresponding pre-treatment score at approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; at day 1, e.g., approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; at day 7; at day 14; and / or at day 28.

[0375] Clinical response in patients with comorbid anxiety and MDD (reflected by a decrease of at least 50% in HAM-D score and at least 50% in HAM-A score compared to the corresponding pre-treatment scores) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. Clinical response in patients with comorbid anxiety and MDD (reflected by a decrease of at least 50% in HAM-D score and at least 50% in HAM-A score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0376] Remission of anxiety-depression or comorbid anxiety and MDD (including treatment-resistant forms of the aforementioned disorders) in patients with anxiety-depression or comorbid anxiety and MDD is reflected as a HAM-A score of 7 or lower and a HAM-D score of 7 or lower at approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28.

[0377] For patients with anxiety-related depression or comorbid anxiety and MDD (including treatment-resistant forms of the disorder), remission of anxiety-related depression or remission of comorbid anxiety and MDD (reflected by a HAM-A score of 7 or lower and a HAM-D score of 7 or lower) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. This remission of anxiety-related depression or remission of comorbid anxiety and MDD (reflected by a HAM-A score of 7 or lower and a HAM-D score of 7 or lower) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0378] Using 5-MeO-DMT or its pharmaceutically acceptable salts to treat patients with MDD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-induced depression, or patients with comorbid anxiety and MDD) reduced or eliminated suicidal ideation.

[0379] Lessening or elimination of suicidal ideation was observed in patients with anxiety-related depression or comorbid anxiety and MDD (including treatment-resistant forms of the aforementioned disorders) approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28 (reflected in a decrease in the MADRS program “Suicidal Thoughts” score).

[0380] The reduction or elimination of suicidal ideation (reflected by a decrease in the MADRS “Suicidal Thoughts” score) in patients with anxiety-induced depression or comorbid anxiety and MDD (including treatment-resistant forms of the disorder) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable saline. The reduction or elimination of suicidal ideation (reflected by a decrease in the MADRS “Suicidal Thoughts” score) in patients with anxiety-induced depression or comorbid anxiety and MDD (including treatment-resistant forms of the disorder) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or its pharmaceutically acceptable saline; particularly for at least 14 days after the last administration of 5-MeO-DMT or its pharmaceutically acceptable saline; more preferably for at least 28 days after the last administration of 5-MeO-DMT or its pharmaceutically acceptable saline.

[0381] Postpartum depression (PPD) is a debilitating mood disorder that occurs during pregnancy or within four weeks after childbirth. More than 50% of women may experience a brief period of low mood or tearfulness after delivery, but a small percentage may develop PPD. Epidemiological studies estimate the prevalence of PPD to be approximately 15%.

[0382] The patient may have moderate or severe PPD, indicated by a Montgomery-Asperger's Depression Rating Scale (MADRS) score of 20 or higher, or a Hamilton Depression Rating Scale (HAM-D) score of 16 or higher. Severe PPD is further considered, indicated by a Montgomery-Asperger's Depression Rating Scale (MADRS) score of 35 or higher, or a Hamilton Depression Rating Scale (HAM-D) score of 27 or higher.

[0383] Patients treated according to the present invention may have a Montgomery-Asperger's Depression Rating Scale (MADRS) score of 20 or higher or a Hamilton Depression Rating Scale (HAM-D) score of 16 or higher.

[0384] Furthermore, patients treated according to the present invention may have a MADRS score of 28 or higher or a HAM-D score of 22 or higher.

[0385] Furthermore, patients treated according to the present invention may have a MADRS score of 35 or higher or a HAM-D score of 25 or higher.

[0386] Patients with PPD may develop a treatment-resistant form of the disorder.

[0387] Anxiety symptoms are a prominent feature of PPD. Anxiety symptoms are significantly more common in women who experience postpartum depression compared to women who do not.

[0388] It is believed that the additional burden of anxiety symptoms may be due to the responsibility of caring for a newborn and severe sleep deprivation.

[0389] Postpartum depression and anxiety not only affect the mother's overall health, but also the way the mother interacts with the child, thus affecting the child's development.

[0390] PPD can be assessed using the Edinburgh Postnatal Depression Scale (EPDS), which evaluates how the mother has felt over the past 7 days. Three of the 10 questions in the questionnaire assess anxiety. The rating scale ranges from "0" (no, not at all) to "3" (yes, most of the time). Anxiety is considered a fundamental component of the PPD diagnosis, with a threshold of 13 on the total score.

[0391] Significant changes in neural activity can be observed in brain regions important for self-regulation, empathy, emotion, and cognition in patients with PPD. PPD is associated with impaired functional connectivity within and / or between resting-state networks, such as the default mode network and the frontoparietal network.

[0392] Anxiety also involves aberrant connections within and / or between resting-state networks (such as default mode networks and salience networks). These aberrant connections can be normalized through treatments according to the present invention.

[0393] Treatment of patients with PPD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-related depression, or patients with comorbid anxiety and PPD) using 5-MeO-DMT or its pharmaceutically acceptable salts reduced or eliminated anxiety and led to improvement in PPD.

[0394] Reduction or elimination of anxiety was observed in patients with PPD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-related depression or comorbid anxiety and PPD) at approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0395] For patients with PPD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-related depression, or patients with comorbid anxiety and PPD), the reduction or elimination of anxiety occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0396] Reduction or elimination of anxiety (reflected by a decrease in HAM-A score) was observed in patients with PPD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-related depression or comorbid anxiety and PPD) at approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0397] For patients with PPD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-related depression, or patients with comorbid anxiety and PPD), the reduction or elimination of anxiety (reflected by a decrease in the HAM-A score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. The reduction or elimination of anxiety (reflected by a decrease in the HAM-A score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0398] Anxiety reduction or elimination was observed in patients with PPD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-related depression or comorbid anxiety and PPD) at approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28 (reflected as a decrease in the score of the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14)).

[0399] For patients with PPD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-related depression, or patients with comorbid anxiety and PPD), the reduction or elimination of anxiety (reflected by a decrease in the score of the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14)) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety (reflected by a decrease in the score of the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14)) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0400] Reduction or elimination of anxiety (reflected as a decrease in the score of the HAM-A Anxiety Item (Item 1)) was observed in patients with PPD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-related depression or comorbid anxiety and PPD) at approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1 after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0401] For patients with PPD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-related depression, or patients with comorbid anxiety and PPD), the reduction or elimination of anxiety (reflected by a decrease in the HAM-A anxiety item (Item 1) score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety (reflected by a decrease in the HAM-A anxiety item (Item 1) score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0402] At approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, for example, approximately 24 hours later; on day 7; on day 14; and / or on day 28, a reduction or elimination of anxiety was observed in patients with PPD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-related depression, or patients with comorbid anxiety and PPD) (reflected as a decrease in anxiety / somatic factors on the Hamilton Depression Rating Scale (HAM-D)).

[0403] For patients with PPD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-related depression, or patients with comorbid anxiety and PPD), the reduction or elimination of anxiety (reflected as a decrease in HAM-D anxiety / somatic factors) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety (reflected as a decrease in HAM-D anxiety / somatic factors) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0404] Reduction or elimination of anxiety was observed in patients with PPD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-related depression or comorbid anxiety and PPD) at approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28 (reflected in a decrease in the HAM-D item scores for “mental anxiety” and / or “physical anxiety”).

[0405] For patients with PPD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-related depression, or patients with comorbid anxiety and PPD), the reduction or elimination of anxiety (reflected by a decrease in the HAM-D item scores for “Mental Anxiety” and / or “Physical Anxiety”) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety (reflected by a decrease in the HAM-D item scores for “Mental Anxiety” and / or “Physical Anxiety”) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0406] Reduction or elimination of anxiety was observed in patients with PPD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-related depression or comorbid anxiety and PPD) at approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28 (reflected in a decrease in the MADRS item “Inner Tension” score).

[0407] For patients with PPD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-related depression, or patients with comorbid anxiety and PPD), the reduction or elimination of anxiety (reflected by a decrease in the MADRS "Inner Tension" score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. The reduction or elimination of anxiety (reflected by a decrease in the MADRS "Inner Tension" score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0408] Reduction or elimination of anxiety (reflected as a decrease in the BPRS item “Anxiety” score) was observed in patients with PPD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-related depression, or patients with comorbid anxiety and PPD) at approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1 after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0409] For patients with PPD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-related depression, or patients with comorbid anxiety and PPD), the reduction or elimination of anxiety (reflected by a decrease in the BPRS item “Anxiety” score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety (reflected by a decrease in the BPRS item “Anxiety” score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0410] Clinical response in patients with anxiety-induced depression is reflected in a decrease of at least 50% in the HAM-D score compared to the corresponding pre-treatment score at approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1 after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt, for example, approximately 24 hours later; on day 7; on day 14; and / or on day 28.

[0411] Clinical response in patients with anxiety-induced depression (reflected by a decrease of at least 50% in the HAM-D score compared to the corresponding pre-treatment score, and a decrease in the HAM-A score to 7 or lower) occurs no later than approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. Clinical response in patients with anxiety-induced depression (reflected by a decrease of at least 50% in the HAM-D score, and a decrease in the HAM-A score to 7 or lower) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0412] Clinical response in patients with comorbid anxiety and PPD was defined as a reduction of at least 50% in HAM-D score and at least 50% in HAM-A score compared to the corresponding pre-treatment score at approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; day 7; day 14; and / or day 28.

[0413] Clinical response in patients with comorbid anxiety and PPD (reflected by a decrease of at least 50% in HAM-D score and at least 50% in HAM-A score compared to the corresponding pre-treatment scores) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. Clinical response in patients with comorbid anxiety and PPD (reflected by a decrease of at least 50% in HAM-D score and at least 50% in HAM-A score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0414] Remission of anxiety-depression or remission of anxiety-MDD in patients with comorbid anxiety-depression or anxiety and PPD (including treatment-resistant forms of the aforementioned disorders) is reflected as a HAM-A score of 7 or lower and a HAM-D score of 7 or lower at approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28.

[0415] For patients with anxiety-related depression or comorbid anxiety and PPD (including treatment-resistant forms of the disorder), remission of anxiety-related depression or remission of comorbid anxiety and MDD (reflected by a HAM-A score of 7 or lower and a HAM-D score of 7 or lower) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. This remission of anxiety-related depression or remission of comorbid anxiety and MDD (reflected by a HAM-A score of 7 or lower and a HAM-D score of 7 or lower) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0416] Treatment of patients with PPD (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with anxiety-induced depression, or patients with comorbid anxiety and PPD) using 5-MeO-DMT or its pharmaceutically acceptable salts reduced or eliminated suicidal ideation.

[0417] Lessening or elimination of suicidal ideation was observed in patients with anxiety-related depression or comorbid anxiety and PPD (including treatment-resistant forms of the aforementioned disorders) approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28 (reflected in a decrease in the MADRS program “Suicidal Thoughts” score).

[0418] The reduction or elimination of suicidal ideation (reflected by a decrease in the MADRS “Suicidal Thoughts” score) in patients with anxiety-induced depression or comorbid anxiety and PPD (including treatment-resistant forms of the aforementioned disorders) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable saline. The reduction or elimination of suicidal ideation (reflected by a decrease in the MADRS “Suicidal Thoughts” score) in patients with anxiety-induced depression or comorbid anxiety and PPD (including treatment-resistant forms of the aforementioned disorders) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or its pharmaceutically acceptable saline; particularly for at least 14 days after the last administration of 5-MeO-DMT or its pharmaceutically acceptable saline; more preferably for at least 28 days after the last administration of 5-MeO-DMT or its pharmaceutically acceptable saline.

[0419] In addition, anxiety can impair maternal function.

[0420] For example, the Barkin Index of Maternal Function (BIMF) can be used to assess maternal function. This index is designed to measure function within one year postpartum. The BIMF is a 20-item self-reported measure of function. Each item is rated from 0 to 6, resulting in a maximum total score of 120. Higher scores indicate better maternal function.

[0421] The BIMF identifies the key functional areas of mothers during the postpartum period as: self-care, infant care, mother-child interaction, maternal mental health, social support, management, and adjustment.

[0422] A BIMF score of 95 or below is considered to represent mild maternal function impairment in this paper, a score of 80 or below is considered to represent maternal function impairment in this paper, and a score of 65 or below is considered to represent severe maternal function impairment in this paper.

[0423] The inventors have determined that increased scores on the BPRS item “Anxiety” and / or the MADRS item “Inner Stress” have a negative impact on maternal function (maternal abilities related to infant interaction and maternal self-care).

[0424] Specifically, the inventors have determined that an increased score for "anxiety" in the BPRS program has a negative impact on two aspects of maternal functioning: interaction with the infant and maternal abilities related to maternal self-care. An increased score for "anxiety" in the BPRS program can impair mental health, social support, and management.

[0425] Conversely, improvements in the BPRS program lead to improvements in maternal function, particularly in the areas of mental health, social support, and / or management within the BIMF functional domain.

[0426] Furthermore, the inventors have determined that an increased score for "inner tension" in the MADRS program has a negative impact on two aspects of maternal functioning (interaction with the infant and maternal abilities related to maternal self-care). As assessed by the BIMF, an increased score for "inner tension" in the MADRS program impairs mother-child interaction and maternal mental health.

[0427] Conversely, improvements in the MADRS program lead to improvements in maternal function, particularly in the areas of mother-child interaction and / or maternal mental health within the BIMF functional domain.

[0428] The inventors concluded that 5-MeO-DMT can be used to treat PPD patients to improve anxiety.

[0429] The inventors also concluded that reducing or eliminating anxiety by treating PPD patients not only led to a decrease in the total MADRS score, but also to an improvement in maternal function, reflected in an increase in the BIMF score.

[0430] A BIMF total score improvement of 10% or more is preferred, with an improvement of 20% or more being ideal.

[0431] Improvement in maternal function in patients with PPD was reflected at least in an improved total BIMF score on day 7, day 14, and / or day 28 following the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt.

[0432] Improvement in maternal function (reflected by an improvement in the total BIMF score) in patients with PPD occurs no later than about 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. Improvement in maternal function (reflected by an improvement in the total BIMF score) preferably persists for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0433] Persistent depressive disorder, also known as dysphoric mood, is a chronic form of depression. A diagnosis of persistent depressive disorder is made if depression is present for most of the days, most of the time, for at least two years. Any asymptomatic periods are less than two months.

[0434] To be depressed, you must have two or more of the following symptoms: 1. hopelessness; 2. lack of energy or fatigue; 3. low self-esteem; 4. decreased sleep (insomnia) or increased sleep (excessive sleep); 5. loss of appetite or overeating; 6. difficulty making decisions or difficulty concentrating.

[0435] Patients with persistent depressive disorder may develop a treatment-resistant form of the disorder.

[0436] Patients with persistent depressive disorder may also exhibit anxiety symptoms but are not diagnosed with an anxiety disorder (subthreshold anxiety).

[0437] The term “subthreshold anxiety” as used in this article specifically refers to a patient’s Hamilton Anxiety Rating Scale (HAM-A) score of at least 9 but less than 18, and / or a Beck Anxiety Scale (BAI) score of at least 11 but less than 16.

[0438] The patient may also be diagnosed with persistent depressive disorder and anxiety disorder, meaning they are considered to have a comorbidity of the two disorders. Such a patient may have a HAM-A score of at least 18 and / or a BAI score of at least 16.

[0439] Anxiety symptoms in patients with persistent depressive disorders (such as patients with the aforementioned disorder and subthreshold anxiety, or patients with a comorbidity of the aforementioned disorder and anxiety) are associated with more severe depression and an increased incidence of suicidal ideation.

[0440] The following scales can be used to assess anxiety in patients with persistent depressive disorder: Hamilton Anxiety Rating Scale (HAM-A); HAM-A Mental Anxiety Subscale (items 1-6 and 14 in total); HAM-A Anxiety Mood Item (item 1); Beck Anxiety Scale (BAI); Hamilton Depression Rating Scale (HAM-D) Anxiety / Somatization Factors (item total: Anxiety (Mental), Anxiety (Physical), Somatic Symptoms (Gastrointestinal), Somatic Symptoms (General), Hypochondriasis, and Insight); HAM-D item “Mental Anxiety” and / or “Physical Anxiety”; Montgomery-Asperger Depression Rating Scale (MADRS) item “Inner Tension”; Brief Psychiatric Rating Scale (BPRS) item “Anxiety”.

[0441] Suicidal ideation can be assessed using the MADRS Project's "Suicidal Thoughts" or the Columbia Suicide Severity Rating Scale (C-SSRS).

[0442] In patients with persistent depressive disorder, altered functional connectivity was observed within and / or between several brain regions associated with processing, regulation, emotional memory, rumination-related cognitive processes, impaired concentration, and physiological arousal. Impaired functional connectivity was observed within and / or between the DMN, salience network, executive control network, and limbic network. This functional connectivity differed significantly from that observed in healthy controls.

[0443] Anxiety also involves aberrant connections within and / or between resting-state networks (such as default mode networks and salience networks). These aberrant connections can be normalized through treatments according to the present invention.

[0444] Treatment of patients with persistent depressive disorders (including treatment-resistant forms of the disorders) and anxiety symptoms (such as patients with the disorders and subthreshold anxiety, or patients with a comorbidity of the disorders and anxiety) with 5-MeO-DMT or its pharmaceutically acceptable salts reduced or eliminated anxiety and led to improvement of the disorders.

[0445] Anxiety reduction or elimination was observed in patients with persistent depressive disorder (such as patients with the disorder and subthreshold anxiety, or patients with comorbidities of the disorder and anxiety) approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, for example, approximately 24 hours later; day 7; day 14; and / or day 28 (including treatment-resistant forms of the disorder).

[0446] For patients with persistent depressive disorder (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with the disorder and subthreshold anxiety, or patients with comorbidities of the disorder and anxiety), the reduction or elimination of anxiety occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0447] Approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; and approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, reduction or elimination of anxiety (reflected as a decrease in HAM-A score) was observed in patients with persistent depressive disorder on day 1, e.g., about 24 hours later; day 7; day 14; and / or day 28 (including treatment-resistant forms of the disorder) and with anxiety symptoms (such as patients with the disorder and subthreshold anxiety, or patients with comorbidities of the disorder and anxiety).

[0448] For patients with persistent depressive disorder (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with the disorder and subthreshold anxiety, or patients with comorbidities of the disorder and anxiety), the reduction or elimination of anxiety (reflected by a decrease in the HAM-A score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. The reduction or elimination of anxiety (reflected by a decrease in the HAM-A score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0449] Approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, a reduction or elimination of anxiety was observed in patients with persistent depressive disorder on day 1, for example, approximately 24 hours later; day 7; day 14; and / or day 28 (including treatment-resistant forms of the disorder) and with anxiety symptoms (such as patients with the disorder and subthreshold anxiety, or patients with a comorbidity of the disorder and anxiety) (reflected as a decrease in the score of the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14).

[0450] For patients with persistent depressive disorder (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with the disorder and subthreshold anxiety, or patients with a comorbidity of the disorder and anxiety), the reduction or elimination of anxiety (reflected by a decrease in the score of the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14)) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. The reduction or elimination of anxiety (reflected by a decrease in the score of the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14)) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0451] Approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, an anxiety reduction or elimination was observed in patients with persistent depressive disorder on day 1, for example, approximately 24 hours later; day 7; day 14; and / or day 28 (including treatment-resistant forms of the disorder) and with anxiety symptoms (such as patients with the disorder and subthreshold anxiety, or patients with a comorbidity of the disorder and anxiety) (reflected as a decrease in the score of the HAM-A Anxiety Item (Item 1).

[0452] For patients with persistent depressive disorder (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with the disorder and subthreshold anxiety, or patients with a comorbidity of the disorder and anxiety), the reduction or elimination of anxiety (reflected by a decrease in the HAM-A anxiety item (Item 1) score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety (reflected by a decrease in the HAM-A anxiety item (Item 1) score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0453] Anxiety reduction or elimination (reflected as a decrease in anxiety / somatic factors on the Hamilton Depression Rating Scale (HAM-D)) was observed in patients with persistent depressive disorder approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof on day 1, e.g., approximately 24 hours later; day 7; day 14; and / or day 28 (including treatment-resistant forms of the disorder) (such as patients with the disorder and subthreshold anxiety, or patients with comorbidities of the disorder and anxiety).

[0454] For patients with persistent depressive disorder (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with the disorder and subthreshold anxiety, or patients with comorbidities of the disorder and anxiety), the reduction or elimination of anxiety (reflected as a decrease in HAM-D anxiety / somatic factors) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety (reflected as a decrease in HAM-D anxiety / somatic factors) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0455] Reduction or elimination of anxiety was observed in patients with persistent depressive disorder (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with the disorder and subthreshold anxiety, or patients with comorbidities of the disorder and anxiety) at approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28. (reflected by a decrease in the HAM-D item scores for “mental anxiety” and / or “physical anxiety”).

[0456] For patients with persistent depressive disorder (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with the disorder and subthreshold anxiety, or patients with a comorbidity of the disorder and anxiety), the reduction or elimination of anxiety (reflected by a decrease in the HAM-D item “Mental Anxiety” and / or “Physical Anxiety” scores) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety (reflected by a decrease in the HAM-D item “Mental Anxiety” and / or “Physical Anxiety” scores) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0457] Anxiety reduction or elimination (reflected as a decrease in the MADRS item “Inner Tension” score) was observed in patients with persistent depressive disorder (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with the disorder and subthreshold anxiety, or patients with comorbidities of the disorder and anxiety) approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28.

[0458] For patients with persistent depressive disorder (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with the disorder and subthreshold anxiety, or patients with a comorbidity of the disorder and anxiety), the reduction or elimination of anxiety (reflected by a decrease in the MADRS “Inner Tension” score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. The reduction or elimination of anxiety (reflected by a decrease in the MADRS “Inner Tension” score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0459] Reduction or elimination of anxiety (reflected as a decrease in the BPRS item “Anxiety” score) was observed in patients with persistent depressive disorder (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with the disorder and subthreshold anxiety, or patients with comorbidities of the disorder and anxiety) approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28.

[0460] For patients with persistent depressive disorder (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with the disorder and subthreshold anxiety, or patients with comorbidities of the disorder and anxiety), the reduction or elimination of anxiety (reflected by a decrease in the BPRS item “Anxiety” score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety (reflected by a decrease in the BPRS item “Anxiety” score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0461] Clinical response in patients with persistent depressive disorder and subthreshold anxiety was reflected in a decrease of at least 50% in HAM-D score compared to the corresponding pre-treatment score at approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1 after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt, for example, approximately 24 hours later; on day 7; on day 14; and / or on day 28.

[0462] Clinical response (reflected by a decrease of at least 50% in HAM-D score compared to the corresponding pre-treatment score and a decrease in HAM-A score to 7 or lower) in patients with persistent depressive disorder and subthreshold anxiety occurred no later than approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt.

[0463] Clinical response (reflected by a decrease of at least 50% in HAM-D score and a decrease in HAM-A score to 7 or lower) in patients with persistent depressive disorder and subthreshold anxiety preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0464] Clinical response in patients with comorbid persistent depressive disorder and anxiety was reflected as a decrease of at least 50% in the HAM-D score and at least 50% in the HAM-A score compared to the corresponding pre-treatment scores approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, e.g., approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0465] Clinical response in patients with comorbid persistent depressive disorder and anxiety (reflected by a decrease of at least 50% in HAM-D score and at least 50% in HAM-A score compared to the corresponding pre-treatment scores) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. Clinical response in patients with comorbid persistent depressive disorder and anxiety (reflected by a decrease of at least 50% in HAM-D score and at least 50% in HAM-A score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0466] For patients with persistent depressive disorder (including treatment-resistant forms of the disorder) and subthreshold anxiety, or patients with comorbidities of the disorder (including treatment-resistant forms) and anxiety, remission is reflected as a HAM-A score of 7 or lower and a HAM-D score of 7 or lower at approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28.

[0467] For patients with persistent depressive disorder (including treatment-resistant forms of the disorder) and subthreshold anxiety, or patients with comorbidities of the disorder (including treatment-resistant forms) and anxiety, remission (reflected by a HAM-A score of 7 or lower and a HAM-D score of 7 or lower) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. Remission (reflected by a HAM-A score of 7 or lower and a HAM-D score of 7 or lower) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0468] Treatment with 5-MeO-DMT or its pharmaceutically acceptable salts reduced or eliminated suicidal ideation in patients with persistent depressive disorder (including treatment-resistant forms of the disorder) and subthreshold anxiety, or in patients with comorbidities of the disorder (including treatment-resistant forms) and anxiety.

[0469] Lessening or elimination of suicidal ideation was observed in patients with persistent depressive disorder (including treatment-resistant forms of the disorder) and subthreshold anxiety, or patients with comorbidities of the disorder (including treatment-resistant forms of the disorder) and anxiety, approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28 (reflected in a decrease in the MADRS program “Suicidal Thoughts” score).

[0470] For patients with persistent depressive disorder (including treatment-resistant forms of the disorder) and subthreshold anxiety, or patients with comorbidities of the disorder (including treatment-resistant forms) and anxiety, the reduction or elimination of suicidal ideation (reflected by a decrease in the MADRS “Suicidal Thoughts” score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. The reduction or elimination of suicidal ideation (reflected by a decrease in the MADRS “Suicidal Thoughts” score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0471] Seasonal affective disorder (SAD) is a mood disorder with a seasonal pattern; symptoms typically begin in the fall and subside in the spring. Many people experience sadness, hopelessness, loss of interest in activities, fatigue, and social withdrawal.

[0472] Patients with seasonal affective disorder may develop a treatment-resistant form of the disorder.

[0473] Patients with seasonal affective disorder may also exhibit anxiety symptoms but are not diagnosed with an anxiety disorder (subthreshold anxiety).

[0474] The term “subthreshold anxiety” as used in this article specifically refers to a patient’s Hamilton Anxiety Rating Scale (HAM-A) score of at least 9 but less than 18, and / or a Beck Anxiety Scale (BAI) score of at least 11 but less than 16.

[0475] The patient may also be diagnosed with seasonal affective disorder and anxiety disorder, meaning they are considered to have comorbidities of these two disorders and anxiety. Such a patient may have a HAM-A score of at least 18 and / or a BAI score of at least 16.

[0476] Anxiety symptoms in patients with seasonal affective disorder (such as those with the aforementioned disorder and subthreshold anxiety, or those with a comorbidity of the aforementioned disorder and anxiety) are associated with more severe depression and an increased incidence of suicidal ideation.

[0477] The following scales can be used to assess anxiety in patients with seasonal affective disorder: Hamilton Anxiety Rating Scale (HAM-A); HAM-A Mental Anxiety Subscale (items 1-6 and 14 in total); HAM-A Anxiety Mood Item (item 1); Beck Anxiety Scale (BAI); Hamilton Depression Rating Scale (HAM-D) Anxiety / Somatization Factors (item total: Anxiety (Mental), Anxiety (Physical), Somatic Symptoms (Gastrointestinal), Somatic Symptoms (General), Hypochondriasis, and Insight); HAM-D item “Mental Anxiety” and / or “Physical Anxiety”; Montgomery-Asperger Depression Rating Scale (MADRS) item “Inner Tension”; Brief Psychiatric Rating Scale (BPRS) item “Anxiety”.

[0478] Suicidal ideation can be assessed using the MADRS Project's "Suicidal Thoughts" or the Columbia Suicide Severity Rating Scale (C-SSRS).

[0479] Compared with healthy controls, resting-state activities involving sensorimotor, attention, and visual processing were altered in patients with seasonal affective disorder.

[0480] Anxiety also involves abnormal connections within and / or between resting-state networks (such as the default mode network, salience network, and sensorimotor network). These abnormal connections can be normalized through treatments according to the present invention.

[0481] Treatment of patients with seasonal affective disorder (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with the disorder and subthreshold anxiety, or patients with a comorbidity of the disorder and anxiety) with 5-MeO-DMT or its pharmaceutically acceptable salts reduced or eliminated anxiety and led to improvement of the disorder.

[0482] Anxiety reduction or elimination was observed in patients with seasonal affective disorder (including treatment-resistant forms of the disorder) at approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, for example, approximately 24 hours later; on day 7; on day 14; and / or on day 28.

[0483] For patients with seasonal affective disorder (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with the disorder and subthreshold anxiety, or patients with a comorbidity of the disorder and anxiety), the reduction or elimination of anxiety occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0484] Anxiety reduction or elimination (reflected as a decrease in HAM-A score) was observed in patients with seasonal affective disorder (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with the disorder and subthreshold anxiety, or patients with comorbidities of the disorder and anxiety) approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28.

[0485] For patients with seasonal affective disorder (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with the disorder and subthreshold anxiety, or patients with comorbidities of the disorder and anxiety), the reduction or elimination of anxiety (reflected by a decrease in the HAM-A score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. The reduction or elimination of anxiety (reflected by a decrease in the HAM-A score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0486] Anxiety reduction or elimination (reflected as a decrease in the score of the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14)) was observed in patients with seasonal affective disorder (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with the disorder and subthreshold anxiety, or patients with a comorbidity of the disorder and anxiety) approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28.

[0487] For patients with seasonal affective disorder (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with the disorder and subthreshold anxiety, or patients with a comorbidity of the disorder and anxiety), the reduction or elimination of anxiety (reflected by a decrease in the score of the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14)) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety (reflected by a decrease in the score of the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14)) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0488] Anxiety reduction or elimination (reflected as a decrease in the HAM-A anxiety item (Item 1) score) was observed in patients with seasonal affective disorder (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with the disorder and subthreshold anxiety, or patients with a comorbidity of the disorder and anxiety) approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28.

[0489] For patients with seasonal affective disorder (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with the disorder and subthreshold anxiety, or patients with a comorbidity of the disorder and anxiety), the reduction or elimination of anxiety (reflected by a decrease in the HAM-A anxiety item (Item 1) score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety (reflected by a decrease in the HAM-A anxiety item (Item 1) score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0490] Anxiety reduction or elimination (reflected as a decrease in anxiety / somatic factors on the Hamilton Depression Rating Scale (HAM-D)) was observed in patients with seasonal affective disorder (including treatment-resistant forms of the disorder) such as patients with the disorder and subthreshold anxiety, or patients with comorbidities of the disorder and anxiety, approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0491] For patients with seasonal affective disorder (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with the disorder and subthreshold anxiety, or patients with comorbidities of the disorder and anxiety), the reduction or elimination of anxiety (reflected as a decrease in HAM-D anxiety / somatic factors) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety (reflected as a decrease in HAM-D anxiety / somatic factors) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0492] Reduction or elimination of anxiety was observed in patients with seasonal affective disorder (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with the disorder and subthreshold anxiety, or patients with comorbidities of the disorder and anxiety) at approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28. (reflected by a decrease in the HAM-D item scores for “mental anxiety” and / or “physical anxiety”).

[0493] For patients with seasonal affective disorder (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with the disorder and subthreshold anxiety, or patients with comorbidities of the disorder and anxiety), the reduction or elimination of anxiety (reflected by a decrease in the HAM-D item “Mental Anxiety” and / or “Physical Anxiety” scores) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. The reduction or elimination of anxiety (reflected by a decrease in the HAM-D item “Mental Anxiety” and / or “Physical Anxiety” scores) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0494] Reduction or elimination of anxiety (reflected in a decrease in the MADRS item “Inner Stress” score) was observed in patients with seasonal affective disorder (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with the disorder and subthreshold anxiety, or patients with a comorbidity of the disorder and anxiety) approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28.

[0495] For patients with seasonal affective disorder (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with the disorder and subthreshold anxiety, or patients with a comorbidity of the disorder and anxiety), the reduction or elimination of anxiety (reflected by a decrease in the MADRS “Inner Tension” score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. The reduction or elimination of anxiety (reflected by a decrease in the MADRS “Inner Tension” score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0496] Reduction or elimination of anxiety (reflected as a decrease in the BPRS item “Anxiety” score) was observed in patients with seasonal affective disorder (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with the disorder and subthreshold anxiety, or patients with a comorbidity of the disorder and anxiety) approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28.

[0497] For patients with seasonal affective disorder (including treatment-resistant forms of the disorder) and anxiety symptoms (such as patients with the disorder and subthreshold anxiety, or patients with a comorbidity of the disorder and anxiety), the reduction or elimination of anxiety (reflected in a decrease in the BPRS item “Anxiety” score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety (reflected in a decrease in the BPRS item “Anxiety” score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0498] Clinical responses in patients with seasonal affective disorder and subthreshold anxiety were reflected as a decrease in HAM-D score of at least 50% compared to the corresponding pre-treatment score and a decrease in HAM-A score to 7 or lower at approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, e.g., approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0499] Clinical responses in patients with seasonal affective disorder and subthreshold anxiety (reflected by a decrease of at least 50% in HAM-D scores compared to the corresponding pre-treatment scores and a decrease in HAM-A scores to 7 or lower) occurred no later than approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt.

[0500] Clinical response in patients with seasonal affective disorder and subthreshold anxiety (reflected by a decrease of at least 50% in HAM-D score and a decrease in HAM-A score to 7 or lower) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0501] Clinical response in patients with comorbid seasonal affective disorder and anxiety was reflected as a decrease in HAM-D score of at least 50% and a decrease in HAM-A score of at least 50% compared to the corresponding pre-treatment scores at approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1 after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt, for example, approximately 24 hours later; on day 7; on day 14; and / or on day 28.

[0502] Clinical response in patients with comorbid seasonal affective disorder and anxiety (reflected by a decrease of at least 50% in HAM-D score and at least 50% in HAM-A score compared to the corresponding pre-treatment scores) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt. Clinical response in patients with comorbid seasonal affective disorder and anxiety (reflected by a decrease of at least 50% in HAM-D score and at least 50% in HAM-A score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; particularly for at least 14 days after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; more preferably for at least 28 days after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt.

[0503] For patients with seasonal affective disorder (including treatment-resistant forms of the disorder) and subthreshold anxiety, or patients with comorbidities of the disorder (including treatment-resistant forms) and anxiety, remission is reflected as a HAM-A score of 7 or lower and a HAM-D score of 7 or lower at approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28.

[0504] For patients with seasonal affective disorder (including treatment-resistant forms of the disorder) and subthreshold anxiety, or patients with comorbidities of the disorder (including treatment-resistant forms) and anxiety, remission (reflected by a HAM-A score of 7 or lower and a HAM-D score of 7 or lower) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. Remission (reflected by a HAM-A score of 7 or lower and a HAM-D score of 7 or lower) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0505] Treatment with 5-MeO-DMT or its pharmaceutically acceptable salts reduced or eliminated suicidal ideation in patients with seasonal affective disorder (including treatment-resistant forms of the disorder) and subthreshold anxiety, or in patients with comorbidities of the disorder (including treatment-resistant forms) and anxiety.

[0506] Lessening or elimination of suicidal ideation was observed in patients with seasonal affective disorder (including treatment-resistant forms of the disorder) and subthreshold anxiety, or patients with comorbidities of the disorder (including treatment-resistant forms of the disorder) and anxiety, approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28 (reflected in a decrease in the MADRS program “Suicidal Thoughts” score).

[0507] For patients with seasonal affective disorder (including treatment-resistant forms of the disorder) and subthreshold anxiety, or patients with comorbidities of the disorder (including treatment-resistant forms) and anxiety, the reduction or elimination of suicidal ideation (reflected by a decrease in the MADRS “Suicidal Thoughts” score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. The reduction or elimination of suicidal ideation (reflected by a decrease in the MADRS “Suicidal Thoughts” score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0508] Bipolar disorder is a mental health condition characterized by dramatic mood swings, including depressed mood (major depressive episodes) and elevated mood (manic or hypomanic episodes). Bipolar disorder is a relapsing chronic disorder affecting more than 1% of the global population, regardless of their racial origin or socioeconomic status.

[0509] If at least one manic episode occurs (whether or not accompanied by a depressive episode), BD is classified as bipolar I. If at least one hypomanic episode (but not a full-blown manic episode) and one major depressive episode occur, BD is classified as bipolar II. If these symptoms are caused by medication or a medical problem, they are not diagnosed as bipolar disorder.

[0510] Patients with BD (including bipolar I and bipolar II) may develop treatment-resistant forms of the disorder.

[0511] Patients with BD, whether diagnosed with bipolar II or bipolar I, are particularly likely to experience a current major depressive episode.

[0512] The severity of a current major depressive episode can be assessed using the Montgomery-Asperger Depression Rating Scale (MADRS). Patients may have a total score of 19 or higher, such as 24 or higher, and especially 37 or higher.

[0513] Alternatively, the patient may have a total score of 19 on the Bipolar Depression Rating Scale (BDRS), such as 24 or greater, especially 37 or greater.

[0514] Anxiety symptoms are common in BD, and the comorbid diagnosis of any anxiety disorder is higher in BD patients than in patients with major depressive disorder.

[0515] In addition, anxiety is a common reported feature of some manic episodes and can therefore be labeled as “mixed manifestations”.

[0516] Patients with BD may also exhibit anxiety symptoms but are not diagnosed with anxiety disorder (subthreshold anxiety).

[0517] The term “subthreshold anxiety” as used in this article specifically refers to a patient’s Hamilton Anxiety Rating Scale (HAM-A) score of at least 9 but less than 18, and / or a Beck Anxiety Scale (BAI) score of at least 11 but less than 16.

[0518] The patient may also be diagnosed with BD and anxiety disorder, meaning they are considered to have comorbid BD and anxiety. Such patients may have a HAM-A score of at least 18 and / or a BAI score of at least 16.

[0519] The presence of comorbid anxiety symptoms is important for identification, as comorbid anxiety disorder increases the suicide risk in people with bipolar disorder.

[0520] The following scales can be used to assess anxiety in patients with BD: Hamilton Anxiety Rating Scale (HAM-A); HAM-A Mental Anxiety Subscale (items 1-6 and 14 in total); HAM-A Anxiety Mood Item (item 1); Beck Anxiety Scale (BAI); Hamilton Depression Rating Scale (HAM-D) Anxiety / Somatization Factors (item total: Anxiety (Mental), Anxiety (Physical), Somatic Symptoms (Gastrointestinal), Somatic Symptoms (General), Hypochondriasis, and Insight); HAM-D item “Mental Anxiety” and / or “Physical Anxiety”; Montgomery-Asperger Depression Rating Scale (MADRS) item “Inner Tension”; Bipolar Depression Rating Scale (BDRS) item “Anxiety”; Brief Psychiatric Rating Scale (BPRS) item “Anxiety”.

[0521] Suicidal ideation can be assessed using the MADRS Project “Suicidal Thoughts”, the BDRS Project “Suicidal Ideation”, or the Columbia Suicide Severity Rating Scale (C-SSRS).

[0522] Patients with bipolar disorder exhibit characteristic abnormalities in internal organization and the interconnectivity of resting-state networks. Compared with healthy controls, resting-state functional magnetic resonance imaging studies have demonstrated altered functional connectivity in specific regions within and / or between the default mode network, salience network, and central executive network.

[0523] Anxiety also involves aberrant connections within and / or between resting-state networks (such as default mode networks and salience networks). These aberrant connections can be normalized through treatments according to the present invention.

[0524] Treatment of patients with BD (including treatment-resistant forms of BD) and anxiety symptoms (such as patients with BD and subthreshold anxiety, or patients with comorbid BD and anxiety) with 5-MeO-DMT or its pharmaceutically acceptable salts reduced or eliminated anxiety and led to improvement in BD.

[0525] Anxiety reduction or elimination was observed in patients with BD (including treatment-resistant forms of BD) such as patients with BD and subthreshold anxiety, or patients with comorbid BD and anxiety, approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0526] For patients with BD (including treatment-resistant forms of BD) and anxiety symptoms (such as patients with BD and subthreshold anxiety, or patients with comorbid BD and anxiety), the reduction or elimination of anxiety occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0527] Anxiety reduction or elimination (reflected as a decrease in HAM-A score) was observed in patients with BD (including treatment-resistant forms of BD) and anxiety symptoms (such as patients with BD and subthreshold anxiety, or patients with comorbid BD and anxiety) at approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0528] For patients with BD (including treatment-resistant forms of BD) and anxiety symptoms (such as patients with BD and subthreshold anxiety, or patients with comorbid BD and anxiety), the reduction or elimination of anxiety (reflected by a decrease in HAM-A score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. The reduction or elimination of anxiety (reflected by a decrease in HAM-A score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0529] Anxiety reduction or elimination was observed in patients with BD (including treatment-resistant forms of BD) and anxiety symptoms (such as patients with BD and subthreshold anxiety, or patients with comorbid BD and anxiety) at approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28 (reflected as a decrease in the score of the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14)).

[0530] For patients with BD (including treatment-resistant forms of BD) and anxiety symptoms (such as patients with BD and subthreshold anxiety, or patients with comorbid BD and anxiety), the reduction or elimination of anxiety (reflected by a decrease in the score of the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14)) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. The reduction or elimination of anxiety (reflected by a decrease in the score of the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14)) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0531] Anxiety reduction or elimination was observed in patients with BD (including treatment-resistant forms of BD) and anxiety symptoms (such as patients with BD and subthreshold anxiety, or patients with comorbid BD and anxiety) at approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28 (reflected as a decrease in the score of the HAM-A Anxiety Item (Item 1)).

[0532] For patients with BD (including treatment-resistant forms of BD) and anxiety symptoms (such as patients with BD and subthreshold anxiety, or patients with comorbid BD and anxiety), the reduction or elimination of anxiety (reflected by a decrease in the HAM-A anxiety item (Item 1) score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety (reflected by a decrease in the HAM-A anxiety item (Item 1) score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0533] Anxiety reduction or elimination was observed in patients with BD (including treatment-resistant forms of BD) (such as patients with BD and subthreshold anxiety, or patients with comorbid BD and anxiety) at approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28 (reflected as a decrease in anxiety / somatic factors on the Hamilton Depression Rating Scale (HAM-D)).

[0534] For patients with BD (including treatment-resistant forms of BD) and anxiety symptoms (such as patients with BD and subthreshold anxiety, or patients with comorbid BD and anxiety), the reduction or elimination of anxiety (reflected as a decrease in HAM-D anxiety / somatic factors) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety (reflected as a decrease in HAM-D anxiety / somatic factors) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0535] Anxiety reduction or elimination was observed in patients with BD (including treatment-resistant forms of BD) and anxiety symptoms (such as patients with BD and subthreshold anxiety, or patients with comorbid BD and anxiety) at approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28 (reflected as a decrease in the HAM-D item scores for “mental anxiety” and / or “physical anxiety”).

[0536] For patients with BD (including treatment-resistant forms of BD) and anxiety symptoms (such as patients with BD and subthreshold anxiety, or patients with comorbid BD and anxiety), the reduction or elimination of anxiety (reflected by a decrease in the HAM-D item scores for “mental anxiety” and / or “physical anxiety”) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. The reduction or elimination of anxiety (reflected by a decrease in the HAM-D item scores for “mental anxiety” and / or “physical anxiety”) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0537] Anxiety reduction or elimination was observed in patients with BD (including treatment-resistant forms of BD) and anxiety symptoms (such as patients with BD and subthreshold anxiety, or patients with comorbid BD and anxiety) at approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28 (reflected in a decrease in the MADRS item “Inner Tension” score).

[0538] For patients with BD (including treatment-resistant forms of BD) and anxiety symptoms (such as patients with BD and subthreshold anxiety, or patients with comorbid BD and anxiety), the reduction or elimination of anxiety (reflected by a decrease in the MADRS "Inner Tension" score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. The reduction or elimination of anxiety (reflected by a decrease in the MADRS "Inner Tension" score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0539] Anxiety reduction or elimination (reflected as a decrease in the BDRS item “Anxiety” score) was observed in patients with BD (including treatment-resistant forms of BD) and anxiety symptoms (such as patients with BD and subthreshold anxiety, or patients with comorbid BD and anxiety) at approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0540] For patients with BD (including treatment-resistant forms of BD) and anxiety symptoms (such as patients with BD and subthreshold anxiety, or patients with comorbid BD and anxiety), the reduction or elimination of anxiety (reflected as a decrease in the BDRS item “Anxiety” score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety (reflected as a decrease in the BDRS item “Anxiety” score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0541] Reduction or elimination of anxiety was observed in patients with BD (including treatment-resistant forms of BD) and anxiety symptoms (such as patients with BD and subthreshold anxiety, or patients with comorbid BD and anxiety) at approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28 (reflected in a decrease in the BPRS item “Anxiety” score).

[0542] For patients with BD (including treatment-resistant forms of BD) and anxiety symptoms (such as patients with BD and subthreshold anxiety, or patients with comorbid BD and anxiety), the reduction or elimination of anxiety (reflected by a decrease in the BPRS item “Anxiety” score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety (reflected by a decrease in the BPRS item “Anxiety” score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0543] Clinical response in patients with BD and subthreshold anxiety was reflected in a decrease of at least 50% in HAM-D score compared to the corresponding pre-treatment score at approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1 after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt, for example, approximately 24 hours later; on day 7; on day 14; and / or on day 28.

[0544] Clinical response (reflected by a decrease of at least 50% in HAM-D score compared to the corresponding pre-treatment score and a decrease in HAM-A score to 7 or lower) in patients with BD and subthreshold anxiety occurred no later than approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt.

[0545] Clinical response in patients with BD and subthreshold anxiety (reflected by a decrease of at least 50% in HAM-D score and a decrease in HAM-A score to 7 or lower) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0546] Clinical response in patients with comorbid BD and anxiety was defined as a reduction of at least 50% in the HAM-D score and at least 50% in the HAM-A score compared to the corresponding pre-treatment scores at approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, e.g., approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0547] Clinical response in patients with comorbid BD and anxiety (reflected by a decrease of at least 50% in HAM-D score and at least 50% in HAM-A score compared to the corresponding pre-treatment scores) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. Clinical response in patients with comorbid BD and anxiety (reflected by a decrease of at least 50% in HAM-D score and at least 50% in HAM-A score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0548] For patients with BD (including treatment-resistant forms of BD) and subthreshold anxiety, or patients with comorbid BD (including treatment-resistant forms) and anxiety, remission is reflected as a HAM-A score of 7 or lower and a HAM-D score of 7 or lower at approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0549] For patients with BD (including treatment-resistant forms of BD) and subthreshold anxiety, or patients with comorbid BD (including treatment-resistant forms) and anxiety, remission (reflected by a HAM-A score of 7 or lower and a HAM-D score of 7 or lower) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. Remission (reflected by a HAM-A score of 7 or lower and a HAM-D score of 7 or lower) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0550] Treatment with 5-MeO-DMT or its pharmaceutically acceptable salts reduced or eliminated suicidal ideation in patients with BD (including treatment-resistant forms of BD) and subthreshold anxiety, or in patients with comorbid BD (including treatment-resistant forms) and anxiety.

[0551] Lessening or elimination of suicidal ideation was observed in patients with BD (including treatment-resistant forms of BD) and subthreshold anxiety, or patients with comorbid BD (including treatment-resistant forms of BD) and anxiety (reflected as a decrease in the MADRS program “Suicidal Ideation” score) approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0552] The reduction or elimination of suicidal ideation (reflected by a decrease in the MADRS “Suicidal Thoughts” score) in patients with BD (including treatment-resistant forms of BD) and subthreshold anxiety, or patients with comorbid BD (including treatment-resistant forms of BD) and anxiety, occurs no later than about 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt. The reduction or elimination of suicidal ideation (reflected by a decrease in the MADRS “Suicidal Thoughts” score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; particularly for at least 14 days after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; more preferably for at least 28 days after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt.

[0553] Lessening or elimination of suicidal ideation was observed in patients with BD (including treatment-resistant forms of BD) and subthreshold anxiety, or patients with comorbid BD (including treatment-resistant forms of BD) and anxiety, approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28 (reflected in a decrease in the BDRS item “Suicidal Ideation” score).

[0554] The reduction or elimination of suicidal ideation (reflected in a decrease in the BDRS “Suicidal Ideation” score) in patients with BD (including treatment-resistant forms of BD) and subthreshold anxiety, or patients with comorbid BD (including treatment-resistant forms of BD) and anxiety, occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of suicidal ideation (reflected in a decrease in the BDRS “Suicidal Ideation” score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0555] Anxiety disorder

[0556] Anxiety disorder is a mental health condition. Symptoms include feelings of tension, panic, and fear, as well as sweating and rapid heartbeat. Anxiety involves a complex system of cognitive, emotional, physiological, and behavioral responses related to preparation for anticipated events or situations perceived as threatening.

[0557] Patients with anxiety disorders may develop treatment-resistant forms of the disorder.

[0558] The Beck Anxiety Scale (BAI) can be used to assess the severity of anxiety disorders. Alternatively, the Hamilton Anxiety Rating Scale (HAM-A); the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14); the HAM-A Anxiety Affect Item (Item 1); and the Brief Psychiatric Rating Scale (BPRS) item “Anxiety” can be used for assessment.

[0559] In addition, anxiety disorders are associated with suicidal ideation.

[0560] The Columbia Suicide Severity Rating Scale (C-SSRS) can be used to assess suicidal ideation.

[0561] Functional magnetic resonance imaging (fMRI) is used to study anxiety disorders. Generally, all anxiety disorders exhibit abnormalities in the default mode network (DMN). Other networks affected by these disorders are the salience network (SN) and the sensorimotor network (SMN). The resting state balance within and / or between each of these networks (e.g., the SMN and SN) relative to the DMN may be abnormal in different anxiety disorders.

[0562] Treatment of patients with anxiety disorders (including treatment-resistant forms of the disorders) with 5-MeO-DMT or its pharmaceutically acceptable salts reduced or eliminated anxiety.

[0563] Anxiety reduction or elimination was observed in patients with anxiety disorders approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, for example, approximately 24 hours later; on day 7; on day 14; and / or on day 28.

[0564] In patients suffering from anxiety disorders, the reduction or elimination of anxiety occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety preferably continues for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0565] Clinical response in patients with anxiety disorders (including treatment-resistant forms of the disorders) is reflected in a decrease of at least 50% in the HAM-A score compared to the corresponding pre-treatment score at approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28.

[0566] Clinical response (reflected by a decrease in HAM-A score of at least 50% compared to the corresponding pre-treatment score) in patients with anxiety disorders (including treatment-resistant forms of said disorders) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. Clinical response (reflected by a decrease in HAM-A score of at least 50%) in patients with anxiety disorders (including treatment-resistant forms of said disorders) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0567] Relief of anxiety in patients with this anxiety disorder (including treatment-resistant forms of the disorder) is reflected in an HAM-A score of 7 or lower approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28.

[0568] For patients suffering from this anxiety disorder (including treatment-resistant forms of the disorder), relief of anxiety (reflected by a HAM-A score of 7 or lower) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. Relief of anxiety (reflected by a HAM-A score of 7 or lower) in patients suffering from this anxiety disorder (including treatment-resistant forms of the disorder) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0569] Anxiety reduction or elimination (reflected as a decrease in the score of the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14)) was observed in patients with anxiety disorders (including treatment-resistant forms of said disorders) approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1 after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0570] For patients suffering from anxiety disorders (including treatment-resistant forms of said disorders), the reduction or elimination of anxiety (reflected by a decrease in the score of the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14)) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. The reduction or elimination of anxiety (reflected by a decrease in the score of the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14)) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0571] Anxiety reduction or elimination (reflected as a decrease in the HAM-A anxiety mood item (item 1) score) was observed in patients with anxiety disorders (including treatment-resistant forms of said disorders) approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0572] For patients suffering from anxiety disorders (including treatment-resistant forms of said disorders), the reduction or elimination of anxiety (reflected by a decrease in the HAM-A anxiety item (Item 1) score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety (reflected by a decrease in the HAM-A anxiety item (Item 1) score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0573] Anxiety reduction or elimination (reflected as a decrease in the BPRS item “Anxiety” score) was observed in patients with anxiety disorders (including treatment-resistant forms of said disorders) approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0574] For patients suffering from anxiety disorders (including treatment-resistant forms of said disorders), the reduction or elimination of anxiety (reflected by a decrease in the BPRS item “Anxiety” score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety (reflected by a decrease in the BPRS item “Anxiety” score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0575] Patients with anxiety disorders (including treatment-resistant forms of the disorders) treated with 5-MeO-DMT or its pharmaceutically acceptable salts experienced a reduction or elimination of suicidal ideation.

[0576] Suicidal ideation was reduced or eliminated in patients with anxiety disorders (including treatment-resistant forms of the disorder) approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, for example, approximately 24 hours later; on day 7; on day 14; and / or on day 28.

[0577] The reduction or elimination of suicidal ideation in patients with anxiety disorders (including treatment-resistant forms of said disorders) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of suicidal ideation preferably continues for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0578] The above applies to general anxiety disorders, including the specific conditions discussed in detail below, and anxiety disorders caused by medical conditions that occur when the medical condition causes extreme fear, anxiety, or panic; other specific anxiety disorders that may be diagnosed if the patient meets most, but not all, of the criteria for an anxiety disorder; and unspecified anxiety disorders; which are usually diagnosed if the patient experiences anxiety or panic but lacks information to fully diagnose another anxiety disorder.

[0579] Separation anxiety disorder is characterized by excessive anxiety about leaving home and / or being separated from people with whom the patient has a strong emotional attachment.

[0580] Separation can cause significant distress for patients, and they may find it difficult to attend school or work due to the separation. Patients with separation anxiety disorder may also experience excessive anxiety about unpleasant events involving important people in their lives, such as family members.

[0581] Patients with separation anxiety disorder may develop a treatment-resistant form of the disorder.

[0582] The Beck Anxiety Scale (BAI) can be used to assess the severity of separation anxiety disorder. Alternatively, the Hamilton Anxiety Rating Scale (HAM-A); the HAM-A Mental Anxiety Subscale (items 1-6 and 14 in total); the HAM-A Anxiety Affect Item (item 1); and the Brief Psychiatric Rating Scale (BPRS) item “Anxiety” can be used for assessment.

[0583] In addition, separation anxiety disorder is associated with suicidal ideation.

[0584] The Columbia Suicide Severity Rating Scale (C-SSRS) can be used to assess suicidal ideation.

[0585] Functional magnetic resonance imaging (fMRI) was used to study dissociation anxiety disorders. Generally, all anxiety disorders exhibit abnormalities in the default mode network (DMN). Other networks affected by these disorders are the salience network (SN) and the sensorimotor network (SMN). The resting state balance within and / or between each of these networks (e.g., the SMN and SN) relative to the DMN may be abnormal in different anxiety disorders.

[0586] Treatment of patients with separation anxiety disorder (including treatment-resistant forms of the disorder) with 5-MeO-DMT or its pharmaceutically acceptable salts reduced or eliminated anxiety.

[0587] Reduction or elimination of anxiety was observed in patients with separation anxiety disorder approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, for example, approximately 24 hours later; on day 7; on day 14; and / or on day 28.

[0588] In patients with separation anxiety disorder, the reduction or elimination of anxiety occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety preferably continues for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0589] Clinical response in patients with separation anxiety disorder (including treatment-resistant forms of the disorder) is reflected in a decrease of at least 50% in the HAM-A score compared to the corresponding pre-treatment score at approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28.

[0590] Clinical response (reflected by a decrease in HAM-A score of at least 50% compared to the corresponding pre-treatment score) in patients with separation anxiety disorder (including treatment-resistant forms of the disorder) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. Clinical response (reflected by a decrease in HAM-A score of at least 50%) in patients with separation anxiety disorder (including treatment-resistant forms of the disorder) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0591] Relief of anxiety in patients with this separation anxiety disorder (including treatment-resistant forms of the disorder) is reflected in an HAM-A score of 7 or lower approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28.

[0592] For patients suffering from this separation anxiety disorder (including treatment-resistant forms of the disorder), relief of anxiety (reflected by a HAM-A score of 7 or lower) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. This relief of anxiety (reflected by a HAM-A score of 7 or lower) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0593] Reduction or elimination of anxiety (reflected as a decrease in the score of the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14)) was observed in patients with separation anxiety disorder (including treatment-resistant forms of the disorder) approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0594] For patients suffering from separation anxiety disorder (including treatment-resistant forms of the disorder), the reduction or elimination of anxiety (reflected by a decrease in the score of the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14)) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety (reflected by a decrease in the score of the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14)) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0595] Reduction or elimination of anxiety (reflected as a decrease in the HAM-A anxiety item (item 1) score) was observed in patients with separation anxiety disorder (including treatment-resistant forms of the disorder) approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0596] For patients suffering from separation anxiety disorder (including treatment-resistant forms of the disorder), the reduction or elimination of anxiety (reflected by a decrease in the HAM-A anxiety item (Item 1) score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety (reflected by a decrease in the HAM-A anxiety item (Item 1) score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0597] Reduction or elimination of anxiety (reflected as a decrease in the BPRS item “Anxiety” score) was observed in patients with separation anxiety disorder (including treatment-resistant forms of the disorder) approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0598] For patients suffering from separation anxiety disorder (including treatment-resistant forms of the disorder), the reduction or elimination of anxiety (reflected by a decrease in the BPRS item “Anxiety” score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety (reflected by a decrease in the BPRS item “Anxiety” score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0599] Treatment of patients with separation anxiety disorder (including treatment-resistant forms of the disorder) with 5-MeO-DMT or its pharmaceutically acceptable salts reduced or eliminated suicidal ideation.

[0600] Suicidal ideation was reduced or eliminated in patients with separation anxiety disorder (including treatment-resistant forms of the disorder) approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, for example, approximately 24 hours later; on day 7; on day 14; and / or on day 28.

[0601] The reduction or elimination of suicidal ideation in patients suffering from separation anxiety disorder (including treatment-resistant forms of the disorder) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of suicidal ideation preferably continues for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0602] agoraphobia is the fear of situations or places that may cause panic, entrapment, helplessness, or embarrassment.

[0603] People suffering from agoraphobia may find it difficult to leave their homes. The thought of leaving home can cause considerable anxiety and even lead to avoidance. Fears of crowds, travel, elevators, movie theaters, shopping malls, etc., can pose significant challenges.

[0604] People with agoraphobia may also experience recurrent panic attacks.

[0605] Patients with agoraphobia may develop a treatment-resistant form of the disorder.

[0606] The Beck Anxiety Scale (BAI) can be used to assess the severity of agoraphobia. Alternatively, the Hamilton Anxiety Rating Scale (HAM-A); the HAM-A Mental Anxiety Subscale (items 1-6 and 14 in total); the HAM-A Anxiety Affect Item (item 1); and the Brief Psychiatric Rating Scale (BPRS) item “Anxiety” can be used for assessment.

[0607] In addition, agoraphobia is associated with suicidal ideation.

[0608] The Columbia Suicide Severity Rating Scale (C-SSRS) can be used to assess suicidal ideation.

[0609] Functional magnetic resonance imaging of individuals with agoraphobia revealed alterations in functional connectivity within and / or between resting-state networks involved in anxiety.

[0610] Treatment of patients with agoraphobia (including treatment-resistant forms of the disorder) with 5-MeO-DMT or its pharmaceutically acceptable salts reduced or eliminated anxiety.

[0611] Anxiety reduction or elimination was observed in patients with agoraphobia approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, for example, approximately 24 hours later; on day 7; on day 14; and / or on day 28.

[0612] The reduction or elimination of anxiety in patients with agoraphobia occurs no later than about 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt. The reduction or elimination of anxiety preferably continues for at least 6 days after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; particularly for at least 14 days after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; more preferably for at least 28 days after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt.

[0613] Clinical response in patients with agoraphobia (including treatment-resistant forms of the disorder) was reflected in a decrease of at least 50% in the HAM-A score compared to the corresponding pre-treatment score at approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, e.g., approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28.

[0614] Clinical response (reflected by a decrease in HAM-A score of at least 50% compared to the corresponding pre-treatment score) in patients with agoraphobia (including treatment-resistant forms of the disorder) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. Clinical response (reflected by a decrease in HAM-A score of at least 50%) in patients with agoraphobia (including treatment-resistant forms of the disorder) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0615] Relief of anxiety in patients with agoraphobia (including treatment-resistant forms of the disorder) is reflected in a HAM-A score of 7 or lower approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0616] For patients suffering from agoraphobia (including treatment-resistant forms of the disorder), relief of anxiety (reflected by a HAM-A score of 7 or lower) occurs no later than approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. This relief of anxiety (reflected by a HAM-A score of 7 or lower) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0617] Anxiety reduction or elimination (reflected as a decrease in the score of the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14)) was observed in patients with agoraphobia (including treatment-resistant forms of the disorder) approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0618] For patients suffering from agoraphobia (including treatment-resistant forms of the disorder), the reduction or elimination of anxiety (reflected by a decrease in the score of the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14)) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. The reduction or elimination of anxiety (reflected by a decrease in the score of the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14)) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0619] Anxiety reduction or elimination (reflected as a decrease in the HAM-A anxiety item (item 1) score) was observed in patients with agoraphobia (including treatment-resistant forms of the disorder) approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0620] For patients suffering from agoraphobia (including treatment-resistant forms of the disorder), the reduction or elimination of anxiety (reflected by a decrease in the HAM-A anxiety item (Item 1) score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety (reflected by a decrease in the HAM-A anxiety item (Item 1) score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0621] Anxiety reduction or elimination (reflected as a decrease in the BPRS item “Anxiety” score) was observed in patients with agoraphobia (including treatment-resistant forms of the disorder) approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0622] For patients suffering from agoraphobia (including treatment-resistant forms of the disorder), the reduction or elimination of anxiety (reflected by a decrease in the BPRS item “Anxiety” score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. The reduction or elimination of anxiety (reflected by a decrease in the BPRS item “Anxiety” score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0623] Treatment of patients with agoraphobia (including treatment-resistant forms of the disorder) with 5-MeO-DMT or its pharmaceutically acceptable salts reduced or eliminated suicidal ideation.

[0624] Lessening or elimination of suicidal ideation was observed in patients with agoraphobia (including treatment-resistant forms of the disorder) approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0625] The reduction or elimination of suicidal ideation in patients suffering from agoraphobia (including treatment-resistant forms of the disorder) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of suicidal ideation preferably continues for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0626] Generalized anxiety disorder (GAD) is characterized by persistent, excessive, and uncontrollable worry about a wide range of situations and problems. People with GAD may anticipate disasters and may worry excessively about money, health, family, work, or other issues.

[0627] An individual is diagnosed with GAD when they experience persistent anxiety about everyday challenges, and this anxiety is disproportionate to the perceived threat. Individuals with GAD typically experience excessive fear that lasts from months to years.

[0628] GAD can interfere with social, professional, or other important functional areas.

[0629] Patients with GAD may develop a treatment-resistant form of the disorder.

[0630] The Beck Anxiety Scale (BAI) can be used to assess the severity of GAD. Alternatively, the Hamilton Anxiety Rating Scale (HAM-A); the HAM-A Mental Anxiety Subscale (items 1-6 and 14 in total); the HAM-A Anxiety Item (item 1); and the Brief Psychiatric Rating Scale (BPRS) item “Anxiety” can be used for assessment.

[0631] In addition, GAD is associated with suicidal ideation.

[0632] The Columbia Suicide Severity Rating Scale (C-SSRS) can be used to assess suicidal ideation.

[0633] Patients with GAD also exhibit altered functional connectivity, particularly within the default mode network.

[0634] Treatment of patients with GAD (including treatment-resistant forms of the disorder) with 5-MeO-DMT or its pharmaceutically acceptable salts reduced or eliminated anxiety.

[0635] Anxiety reduction or elimination was observed in patients with GAD approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, for example, approximately 24 hours later; on day 7; on day 14; and / or on day 28.

[0636] The reduction or elimination of anxiety in patients with GAD occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety preferably continues for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0637] Clinical response in patients with GAD (including treatment-resistant forms of the aforementioned disorder) is reflected in a decrease of at least 50% in the HAM-A score compared to the corresponding pre-treatment score at approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28.

[0638] Clinical response (reflected by a decrease in HAM-A score of at least 50% compared to the corresponding pre-treatment score) in patients with GAD (including treatment-resistant forms of the disorder) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. Clinical response (reflected by a decrease in HAM-A score of at least 50%) in patients with GAD (including treatment-resistant forms of the disorder) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0639] Anxiety relief in patients with this GAD (including treatment-resistant forms of the disorder) is reflected in an HAM-A score of 7 or lower approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28.

[0640] For patients with this GAD (including treatment-resistant forms of the disorder), relief of anxiety (reflected by a HAM-A score of 7 or lower) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. Relief of anxiety (reflected by a HAM-A score of 7 or lower) in patients with this GAD (including treatment-resistant forms of the disorder) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0641] Anxiety reduction or elimination (reflected as a decrease in the score of the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14)) was observed in patients with GAD (including treatment-resistant forms of the disorder) approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0642] For patients with GAD (including treatment-resistant forms of the disorder), the reduction or elimination of anxiety (reflected by a decrease in the score of the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14)) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. The reduction or elimination of anxiety (reflected by a decrease in the score of the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14)) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0643] Anxiety reduction or elimination (reflected as a decrease in the HAM-A anxiety item (item 1) score) was observed in patients with GAD (including treatment-resistant forms of the disorder) approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0644] For patients with GAD (including treatment-resistant forms of the disorder), the reduction or elimination of anxiety (reflected by a decrease in the HAM-A anxiety item (Item 1) score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety (reflected by a decrease in the HAM-A anxiety item (Item 1) score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0645] Anxiety reduction or elimination (reflected as a decrease in the BPRS item “Anxiety” score) was observed in patients with GAD (including treatment-resistant forms of the aforementioned disorder) approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0646] For patients with GAD (including treatment-resistant forms of the disorder), the reduction or elimination of anxiety (reflected by a decrease in the BPRS item “Anxiety” score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety (reflected by a decrease in the BPRS item “Anxiety” score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0647] Treatment of patients with GAD (including treatment-resistant forms of the disorder) with 5-MeO-DMT or its pharmaceutically acceptable salts reduced or eliminated suicidal ideation.

[0648] Suicidal ideation was reduced or eliminated in patients with GAD (including treatment-resistant forms of the disorder) approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0649] The reduction or elimination of suicidal ideation in patients with GAD (including treatment-resistant forms of the disorder) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of suicidal ideation preferably continues for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0650] Social anxiety disorder (SAD), also known as social phobia, is one of the most common types of anxiety.

[0651] SAD is characterized by intense anxiety or fear of judgment, negative evaluation, or rejection in social or performance situations. This often leads to avoidance of social situations and can impair learning, work, or interpersonal relationships.

[0652] Patients with SAD may develop a treatment-resistant form of the disorder.

[0653] The Beck Anxiety Scale (BAI) can be used to assess the severity of SAD. Alternatively, the Hamilton Anxiety Rating Scale (HAM-A); the HAM-A Mental Anxiety Subscale (items 1-6 and 14 in total); the HAM-A Anxiety Item (item 1); and the Brief Psychiatric Rating Scale (BPRS) item “Anxiety” can be used for assessment.

[0654] In addition, SAD is associated with suicidal ideation.

[0655] The Columbia Suicide Severity Rating Scale (C-SSRS) can be used to assess suicidal ideation.

[0656] In patients with SAD, altered functional connectivity was observed within and / or between resting state networks (such as the default mode network and the salience network).

[0657] Treatment of patients with SAD (including treatment-resistant forms of the disorder) with 5-MeO-DMT or its pharmaceutically acceptable salts reduced or eliminated anxiety.

[0658] Anxiety reduction or elimination was observed in patients with SAD approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, for example, approximately 24 hours later; on day 7; on day 14; and / or on day 28.

[0659] The reduction or elimination of anxiety in patients with SAD occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety preferably continues for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0660] Clinical response in patients with SAD (including treatment-resistant forms of the disorder) is reflected in a decrease of at least 50% in the HAM-A score compared to the corresponding pre-treatment score at approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28.

[0661] Clinical response (reflected by a decrease in HAM-A score of at least 50% compared to the corresponding pre-treatment score) in patients with SAD (including treatment-resistant forms of the disorder) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. Clinical response (reflected by a decrease in HAM-A score of at least 50%) in patients with SAD (including treatment-resistant forms of the disorder) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0662] Anxiety relief in patients with this type of SAD (including treatment-resistant forms of the disorder) is reflected in an HAM-A score of 7 or lower approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28.

[0663] For patients with this type of SAD (including treatment-resistant forms of the disorder), relief of anxiety (reflected by a HAM-A score of 7 or lower) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. Relief of anxiety (reflected by a HAM-A score of 7 or lower) in patients with this type of SAD (including treatment-resistant forms of the disorder) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0664] Anxiety reduction or elimination (reflected as a decrease in the score of the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14)) was observed in patients with SAD (including treatment-resistant forms of the disorder) approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0665] For patients with SAD (including treatment-resistant forms of the disorder), the reduction or elimination of anxiety (reflected by a decrease in the score of the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14)) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof. The reduction or elimination of anxiety (reflected by a decrease in the score of the HAM-A Mental Anxiety Subscale (the sum of items 1-6 and 14)) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable saline thereof.

[0666] Anxiety reduction or elimination (reflected as a decrease in the HAM-A anxiety item (item 1) score) was observed in patients with SAD (including treatment-resistant forms of the disorder) approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0667] For patients with SAD (including treatment-resistant forms of the disorder), the reduction or elimination of anxiety (reflected by a decrease in the HAM-A anxiety item (Item 1) score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety (reflected by a decrease in the HAM-A anxiety item (Item 1) score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0668] Anxiety reduction or elimination (reflected as a decrease in the BPRS item “Anxiety” score) was observed in patients with SAD (including treatment-resistant forms of the disorder) approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0669] For patients with SAD (including treatment-resistant forms of the disorder), the reduction or elimination of anxiety (reflected by a decrease in the BPRS item “Anxiety” score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of anxiety (reflected by a decrease in the BPRS item “Anxiety” score) preferably persists for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0670] Treatment of patients with SAD (including treatment-resistant forms of the disorder) with 5-MeO-DMT or its pharmaceutically acceptable salts reduced or eliminated suicidal ideation.

[0671] Suicidal ideation was reduced or eliminated in patients with SAD (including treatment-resistant forms of the disorder) approximately 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 1, for example, approximately 24 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; on day 7; on day 14; and / or on day 28.

[0672] The reduction or elimination of suicidal ideation in patients with SAD (including treatment-resistant forms of the disorder) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of suicidal ideation preferably continues for at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; particularly for at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably for at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0673] Anxiety is a core characteristic of panic disorder. Patients with panic disorder experience spontaneous panic attacks, characterized by intense fear or discomfort that suddenly peaks within minutes.

[0674] Panic attacks are characterized by a variety of somatic symptoms of anxiety, including sweating, trembling, shaking, headache, palpitations, shortness of breath, chest pain, abdominal pain, and nausea.

[0675] Furthermore, a characteristic of this disorder is often anxiety about future panic attacks. Patients may be extremely worried about a recurrence of the illness.

[0676] Patients with panic disorder may develop a treatment-resistant form of the disorder.

[0677] The Beck Anxiety Scale (BAI) can be used to assess the severity of panic disorder. Alternatively, the Hamilton Anxiety Rating Scale (HAM-A); the HAM-A Mental Anxiety Subscale (items 1-6 and 14 in total); the HAM-A Anxiety Item (item 1); and the Brief Psychiatric Rating Scale (BPRS) item “Anxiety” can be used for assessment.

[0678] In addition, panic disorder is associated with suicidal ideation.

[0679] The Columbia Suicide Severity Rating Scale (C-SSRS) can be used to assess suicidal ideation.

[0680] Patients with panic disorder exhibit alterations in the functional connectivity within and / or between the default mode network and the sensorimotor network.

[0681] Treatment of patients with panic disorder (including treatment-resistant forms of the disorder) with 5-MeO-DMT or its pharmaceutically acceptable salts reduced or eliminated anxiety.

[0682] Anxiety reduction or elimination was observed in patients with panic disorder approximately 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, for example, approximately 24 hours later; on day 7; on day 14; and / or on day 28.

[0683] The reduction or elimination of anxiety in patients with panic disorder occurs no later than about 2 hours after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt. The reduction or elimination of anxiety preferably continues for at least 6 days after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; particularly for at least 14 days after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt; more preferably for at least 28 days after the last administration of 5-MeO-DMT or its pharmaceutically acceptable salt.

[0684] Clinical response in patients with panic disorder (including treatment-resistant forms of the disorder) is reflected in a decrease of at least 50% in HAM-A score compared to the corresponding pre-treatment score at approximately 2 hours after the last adminis...

Claims

1. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for use in treating a patient suffering from anxiety, wherein the 5-MeO-DMT is administered via intravenous, intramuscular or subcutaneous routes.

2. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 1, wherein the anxiety suffered by the patient is subthreshold anxiety.

3. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 1 or claim 2, wherein the patient suffers from comorbidity of anxiety and another diagnosed disorder.

4. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 3, wherein the patient also suffers from a mental or nervous system disorder.

5. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 4, wherein the patient also suffering from a psychiatric or neurological disorder suffers from a treatment-resistant form of said disorder.

6. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use according to claims 1 to 3, wherein the patient also suffers from a disorder characterized by a depressive episode.

7. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use according to claim 6, wherein the patient also suffering from a disorder characterized by a depressive episode suffers from a treatment-resistant form of the disorder.

8. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use according to claims 1 to 3, wherein the patient also suffers from major depressive disorder (MDD).

9. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use according to claim 8, wherein the patient also suffering from MDD suffers from a treatment-resistant form of the disorder.

10. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 3, wherein the patient also suffers from postpartum depression (PPD).

11. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 10, wherein the patient also suffering from PPD suffers from a treatment-resistant form of the disorder.

12. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 10 or 11, wherein the patient also suffers from impaired maternal function.

13. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 12, wherein the patient has a Barkin Index of Maternal Functioning (BIMF) score of 80 or less, such as 65 or less.

14. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 12 or 13, wherein said treatment improves maternal function.

15. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use according to claim 14, wherein the improvement in maternal function is reflected in an improvement in the BIMF total score of 10% or more, preferably 20% or more.

16. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 14 or 15, wherein said improvement in maternal function is reflected at least in an improvement in the BIMF total score at day 7; day 14; and / or day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

17. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 14 or 15, wherein said improvement in maternal function occurs no later than about 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, said improvement being reflected at least in an improvement in the BIMF total score, and wherein said improvement in maternal function persists until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, said improvement being reflected at least in an improvement in the BIMF total score.

18. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 3, wherein the patient also suffers from persistent depressive disorder.

19. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use according to claim 18, wherein the patient who also suffers from persistent depressive disorder suffers from a treatment-resistant form of the disorder.

20. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 3, wherein the patient also suffers from seasonal affective disorder.

21. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 20, wherein the patient who also suffers from seasonal affective disorder suffers from a treatment-resistant form of the disorder.

22. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 3, wherein the patient also suffers from bipolar disorder.

23. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 22, wherein the patient also suffers from bipolar disorder type II.

24. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 22, wherein the patient also suffers from bipolar disorder type I.

25. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 22 to 24, wherein the patient suffers from a current major depressive episode.

26. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 22 to 25, wherein the patient also suffering from bipolar disorder suffers from a treatment resistant form of the disorder.

27. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 1, wherein the patient suffers from an anxiety disorder.

28. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use according to claim 27, wherein the patient suffering from an anxiety disorder suffers from a treatment-resistant form of the disorder.

29. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 1, wherein the patient suffers from separation anxiety disorder.

30. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 29, wherein the patient suffering from separation anxiety disorder suffers from a treatment-resistant form of the disorder.

31. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 1, wherein the patient suffers from agoraphobia.

32. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 31, wherein the patient suffering from agoraphobia suffers from a treatment-resistant form of the disorder.

33. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 1, wherein the patient suffers from generalized anxiety disorder (GAD).

34. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 33, wherein the patient suffering from GAD suffers from a treatment-resistant form of the disorder.

35. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 1, wherein the patient suffers from social anxiety disorder (SAD).

36. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 35, wherein the patient suffering from SAD suffers from a treatment-resistant form of the disorder.

37. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 1, wherein the patient suffers from panic disorder.

38. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 37, wherein the patient suffering from panic disorder suffers from a treatment-resistant form of the disorder.

39. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 1, wherein the patient suffers from a phobia.

40. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 39, wherein the patient suffering from a phobia suffers from a treatment-resistant form of the disorder.

41. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 1, wherein the patient suffers from substance / medication induced anxiety disorder.

42. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 41, wherein the patient suffering from substance / medication induced anxiety disorder suffers from a treatment resistant form of the disorder.

43. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 3, wherein the patient also suffers from somatic symptom disorder.

44. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 43, wherein the patient also suffering from a somatic symptom disorder suffers from a treatment-resistant form of the disorder.

45. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 3, wherein the patient also suffers from obsessive compulsive disorder or a related disorder.

46. ​​5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 45, wherein the obsessive compulsive disorder or related disorder is obsessive compulsive disorder (OCD).

47. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 45 or 46, wherein the patient suffers from a treatment-resistant form of the disorder.

48. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 3, wherein the patient also suffers from body dysmorphic disorder (BDD).

49. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 48, wherein the patient also suffering from BDD suffers from a treatment-resistant form of the disorder.

50. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 3, wherein the patient also suffers from post-traumatic stress disorder (PTSD).

51. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 50, wherein the patient also suffering from PTSD suffers from a treatment-resistant form of the disorder.

52. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 3, wherein the patient also suffers from a pain disorder.

53. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 52, wherein the patient also suffers from chronic pain.

54. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 52 or 53, wherein the patient suffers from a treatment-resistant form of the disorder.

55. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 3, wherein the patient also suffers from fibromyalgia.

56. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 3, wherein the patient also suffers from migraine.

57. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 3, wherein the patient also suffers from mental and behavioral disorders due to the use of psychoactive substances.

58. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 57, wherein the mental and behavioral disorder caused by the use of psychoactive substances that the patient also suffers from is a substance use disorder (SUD).

59. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 57 or 58, wherein the patient suffers from a treatment-resistant form of the disorder.

60. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 3, wherein the patient also suffers from a psychotic disorder.

61. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 60, wherein the patient also suffering from a psychotic disorder suffers from a treatment-resistant form of the disorder.

62. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 3, wherein the patient also suffers from schizophrenia.

63. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 62, wherein the patient also suffering from schizophrenia suffers from a treatment-resistant form of the disorder.

64. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 3, wherein the patient also suffers from Parkinson's disease.

65. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 3, wherein the patient also suffers from dementia.

66. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 3, wherein the patient also suffers from Alzheimer's disease dementia.

67. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 3, wherein the patient also suffers from Parkinson's disease dementia.

68. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 3, wherein the patient also suffers from Lewy body dementia.

69. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 3, wherein the patient also suffers from vascular dementia.

70. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 3, wherein the patient also suffers from frontotemporal dementia.

71. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 3, wherein the patient also suffers from an eating disorder.

72. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 71, wherein the patient who also suffers from an eating disorder suffers from a treatment-resistant form of the disorder.

73. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 3, wherein the patient also suffers from attention deficit hyperactivity disorder (ADHD).

74. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 73, wherein the patient also suffering from ADHD suffers from a treatment-resistant form of the disorder.

75. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 3, wherein the patient also suffers from a personality disorder.

76. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 75, wherein the personality disorder also suffered by the patient is schizotypal personality disorder.

77. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 75 or 76, wherein the patient suffers from a treatment-resistant form of the disorder.

78. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 3, wherein the patient also suffers from borderline personality disorder (BPD).

79. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 78, wherein the patient also suffering from BPD suffers from a treatment-resistant form of the disorder.

80. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 3, wherein the patient also suffers from chronic fatigue syndrome.

81. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 3, wherein the patient also suffers from an autism spectrum disorder.

82. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as described in claims 1 to 3, wherein the patient suffers from a traumatic brain injury and also suffers from said anxiety.

83. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 3, wherein the patient suffers from HIV infection and also suffers from said anxiety.

84. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as described in claims 1 to 3, wherein the patient suffers from post-COVID sequelae and also suffers from the anxiety.

85. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as described in claims 1 to 84, wherein said treatment reduces or eliminates said anxiety.

86. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as described in claim 85, wherein the reduction or elimination of anxiety is observed at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at 1 day, such as about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at 7 days; at 14 days; and / or at 28 days.

87. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as described in claim 85, wherein the reduction or elimination of anxiety occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, and wherein the reduction or elimination of anxiety lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

88. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as described in claims 4 to 26 and 43 to 87, wherein said treatment results in improvement of said diagnosed disorder in a patient who also suffers from anxiety.

89. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as described in claim 88, wherein said improvement in said diagnosed disorder in a patient who also suffers from anxiety is observed as a decrease in a Clinical Global Impression - Severity (CGI-S) score at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

90. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as described in claim 88, wherein said improvement in said diagnosed disorder in a patient who also suffers from anxiety occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, said improvement being reflected in a decrease in the Clinical Global Impression-Severity (CGI-S) score, and wherein said improvement in said diagnosed disorder in a patient who also suffers from anxiety persists until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, said improvement being reflected in a decrease in the Clinical Global Impression-Severity (CGI-S) score.

91. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as described in claims 1 to 3, wherein the patient also suffers from a sleep disorder.

92. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 91, wherein the sleep disorder is insomnia.

93. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 91 or 92, wherein the patient suffers from a treatment-resistant form of the disorder.

94. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as described in claims 91 to 93, wherein the sleep disturbance occurs in a patient who also suffers from anxiety and who also suffers from a psychiatric or neurological disorder, such as a disorder characterized by depressive episodes, for example, major depressive disorder (MDD), postpartum depression (PPD), persistent depressive disorder, seasonal affective disorder, and bipolar disorder (BD), such as bipolar disorder type I and bipolar disorder type II; anxiety disorders, such as separation anxiety disorder, agoraphobia, generalized anxiety disorder (GAD), social anxiety disorder (SAD), panic disorder, phobias, and substance / medication-induced anxiety disorders; somatic symptom disorder; obsessive-compulsive disorder and related disorders, such as obsessive-compulsive disorder (OCD) and body dysmorphic disorder (BDD); post-traumatic stress disorder (PTSD); pain disorders, such as chronic pain, fibromyalgia, and migraines; mental and behavioral disorders due to the use of psychoactive substances, such as substance use disorders (SUD); psychotic disorders, such as schizophrenia; Parkinson's disease; dementias, such as Alzheimer's disease dementia (AD), Parkinson's disease dementia (PDD), dementia with Lewy bodies, vascular dementia, and frontotemporal dementia; eating disorders; Attention deficit hyperactivity disorder (ADHD); personality disorders, such as schizotypal personality disorder and borderline personality disorder; autism spectrum disorder; chronic fatigue syndrome; or a medical health condition that results in associated psychiatric or neurological impairment, such as anxiety caused by traumatic brain injury (TBI), HIV infection, or post-COVID syndrome.

95. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 94, wherein the treatment results in improvement of anxiety and sleep disturbances and further results in improvement of the related psychiatric or neurological disorder or in improvement of the medical health condition of the related psychiatric or neurological disorder.

96. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as described in claims 85 to 95, wherein said treatment results in an improvement in said sleep disorder.

97. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as described in claim 96, wherein the improvement in the sleep disturbance is observed on the 1st day, such as about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on the 7th day; on the 14th day; and / or on the 28th day after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, and the improvement is reflected in a decrease in the Clinical Global Impression-Severity (CGI-S) score.

98. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as described in claim 96, wherein said improvement in said sleep disturbance occurs no later than about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, said improvement being reflected in a decrease in the Clinical Global Impression-Severity (CGI-S) score, and wherein said improvement in said sleep disturbance persists until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, said improvement being reflected in a decrease in the Clinical Global Impression-Severity (CGI-S) score.

99. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 96, wherein said improvement in said sleep disturbance, as reflected by a decrease in the Clinical Global Impression-Severity (CGI-S) score, is observed on the 7th day after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, and preferably lasts until at least 14 days, more preferably until at least 28 days.

100. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 99, wherein the patient suffers from suicidal ideation and the treatment reduces or eliminates suicidal ideation.

101. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 100, wherein the 5-MeO-DMT or a salt thereof is administered at a dose or dosage regimen that causes the patient to experience a peak psychedelic experience.

102. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 101, wherein a dosage of about 1 mg to about 10 mg of 5-MeO-DMT is administered, or wherein an equimolar amount of said pharmaceutically acceptable salt is administered instead of 5-MeO-DMT.

103. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as described in claims 1 to 101, wherein a dose of about 2 mg; or about 5 mg; or about 8 mg is administered, or wherein an equimolar amount of said pharmaceutically acceptable salt is administered in place of 5-MeO-DMT.

104. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as described in claims 1 to 101, wherein a dose of about 1 mg; or about 2 mg; or about 3 mg is administered, or wherein an equimolar amount of said pharmaceutically acceptable salt is administered in place of 5-MeO-DMT.

105. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as described in claims 1 to 102, wherein the 5-MeO-DMT or a salt thereof is administered in a first dose in a first administration; and the 5-MeO-DMT or a salt thereof is administered in zero to six subsequent administrations; wherein, Unless the patient is experiencing a peak psychedelic experience, each subsequent administration uses a higher dose than the previous one.

106. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as described in claims 1 to 102 or 105, wherein the 5-MeO-DMT is administered at a dose of about 1 mg to about 3 mg for a first administration, then increased to a dose of about 4 mg to about 6 mg for a second administration unless the patient has experienced a peak psychedelic experience, then increased to a dose of about 7 mg to about 9 mg for a third administration unless the patient has experienced a peak psychedelic experience, or wherein an equimolar amount of the pharmaceutically acceptable salt is administered in place of the 5-MeO-DMT.

107. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as described in claim 106, wherein the first dose of 5-MeO-DMT is about 2 mg, the second dose of 5-MeO-DMT is about 5 mg, and the third dose of 5-MeO-DMT is about 8 mg; or wherein an equimolar amount of the pharmaceutically acceptable salt is administered in place of 5-MeO-DMT.

108. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as described in claims 1 to 102 or 105, wherein the 5-MeO-DMT is administered at a dose of about 0.5 mg to about 1.5 mg for a first administration, then increased to a dose of about 1.5 mg to about 2.5 mg for a second administration unless the patient has experienced a peak psychedelic experience, then increased to a dose of about 2.5 mg to about 3.5 mg for a third administration unless the patient has experienced a peak psychedelic experience, or wherein an equimolar amount of the pharmaceutically acceptable salt is administered in place of the 5-MeO-DMT.

109. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as described in claim 108, wherein the first dose of 5-MeO-DMT is about 1 mg, the second dose of 5-MeO-DMT is about 2 mg, and the third dose of 5-MeO-DMT is about 3 mg; or wherein an equimolar amount of the pharmaceutically acceptable salt is administered in place of 5-MeO-DMT.

110. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as described in claims 105 to 109, wherein the interval between two administrations is not less than 1 hour and not more than 24 hours, such as about 1 to 4 hours, preferably 1 to 2 hours.

111. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as described in claims 101 to 110, wherein the occurrence of the peak psychedelic experience is identified by achieving at least 60% of the maximum possible score in each of the four subscales (mystical, positive emotions, transcendence of time and space, and ineffable) of the 30-item revised Mystical Experience Questionnaire (MEQ30), or by achieving at least 60% of the maximum possible score on the Oceanic Boundlessness (OBN) dimension of the Altered States of Consciousness (ASC) Questionnaire, or by achieving a Peak Experience Scale (PES) total score of at least 75.

112. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 111, wherein the occurrence of the peak psychedelic experience is identified by achieving a Peak Experience Scale (PES) total score of at least 75.

113. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 112, wherein the 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered via intravenous injection.

Citation Information

Patent Citations

  • 5-methoxy-n,n-dimethyltryptamine (5-MEO-DMT) for treating depression

    WO2020169850A1